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Decreasing the number of people who die from preventable illnesses and reducing 
poverty and inequality are major public goods that are being addressed from a variety of 
angles. One way that policy makers and scholars are trying to improve global health is by 
developing new health technologies that will decrease poverty and inequality. This 
dissertation investigates whether nanotechnologies for medical applications (NM) are 
used to address diseases of poverty (DoP) and the role that public-private partnerships 
(PPP) play in NM research. If scientists are developing nanotechnology based vaccines 
and medicines for DoP, then I can conclude that the technology is helping to decrease 
poverty and inequality.  
There are two parts to my analysis. The first part of my dissertation analyses the 
landscape of NM DoP research, and then I test how USA medicine sales, disease burden, 
and DoP correlate with the number of NM publications and patents. I find that there is 
some NM research on DoP, especially for high-profile DoP such as malaria, tuberculosis 
and HIV/AIDS, but overall there is less R&D on DoP than non-DoP. However, I cannot 
determine if USA medicine sales and disease burden have any relationship to research 
output.  
 In the second part of my dissertation, I examine the role of formal PPPs for 
developing DoP medicines. Many think the formal health PPPs can overcome the various 
market failures associated with developing medicines for DoP. I analyze PPP websites, 
and I interview PPP managers/scientists about their research portfolios, their relationships 




R&D. I find that managers/scientists at PPPs have a variety of opinions about 
nanotechnology, but the general consensus is that nanotechnology will not be used in the 
near-term for DoP medicines. PPP managers/scientists believe that the technology is too 
expensive for DoP medicines and it will take too long to approve NMs. Instead of using 




CHAPTER 1: INTRODUCTION 
 
 
Ensuring that people are healthy is one of the major global public goods, and for 
millennia, doctors have tried a variety of techniques to keep people from getting sick 
(Feachem & Sachs, 2002). Many of the most deadly diseases were eliminated through a 
variety of technologies and social improvements such as better medications, new 
treatment regimens, and cleaner communities that prevented pestilence from spreading. 
Despite the improvements in overall health, the advancements in healthcare are not 
evenly distributed. Many medical discoveries only target diseases of the rich while other 
medicines are too expensive for impoverished communities to purchase. At one point, 
scholars estimated that there was a “10-90 gap.” This dissertation explores how an 
emerging technology, nanotechnology, is used to address DoP and the role that PPPs 
have in this research. Chapter 1 gives a brief overview of the literature, research 
questions, methods, and the significance of the study. I start by discussing the main 
literature used in the dissertation. I review the public health literature; science, 
technology, and innovation policy literature; and public policy/administration literatures. 
Then, I give an overview of the three main research questions of the dissertation and the 
methods I use to address these questions. I use both quantitative and qualitative data from 
publications, patents, websites, and interviews. Finally, the last section of the chapter 
outlines the significance of this study. Overview of Literature 
There are about 40 DoP (Global Forum for Health Research, 2004), and the health 
literature attributes a large proportion of global healthcare inequality to the lack of a 




biotechnology and pharmaceutical companies will not develop new medicines to target 
DoP if they cannot recoup their R&D expenses. As a result, there is a lack of R&D and 
medicines for DoP. The research gap is a major market failure that needs to be addressed 
in order to improve the global public health (Feachem & Sachs, 2002).  
To correct the market imbalances, many scholars believe that special 
organizational structures, such as PPPs, are necessary (Moran, Guzman, Ropars, & 
Illmer, 2010; World Health Organization, 2010a). PPPs can provide research funds, 
connect companies to government health organizations, participate in manufacturing, and 
assist with distribution and marketing (Glennerster, Kremer, & Williams, 2006; Widdus, 
2001). These efforts can spur new DoP drug development and make the current 
medicines for DoP more accessible.  
The term “public-private partnership” was first used about 40 years ago, and now 
the PPP is a very common organizational structure that is promoted by politicians and 
scholars (Bovaird, 2004). PPP scholarship arises from several disciplines, but this 
dissertation examines PPPs from a public management and administration viewpoint 
because it most clearly defines PPPs. From this discipline, PPPs are defined as “working 
arrangements based on a mutual commitment (over and above that implied in any 
contract) between a public sector organization with any organization outside of the public 
sector” (Bovaird, 2004). This dissertation focuses on a subset of PPPs that conduct R&D 
for DoP. These formal PPPs are operationally and legally institutionally independent 
from the collaborating organizations, and they are extremely influential for DoP research 
(Hanlin et al., 2007).  One study estimates that 75% of all research on DoP is done by 




There are a variety of formal PPPs, but a goal shared by many them is drug 
discovery. Scientists have long believed that new and emerging technologies could 
revolutionize healthcare and improve lives. However, emerging technologies are often 
associated with high-tech societies, and rarely have scientists worried about the 
distributional consequences of the technology. Therefore, there is an interesting 
intersection between PPPs, emerging technologies, and DoP. According to current 
academic theory, PPPs can act as the conduit for emerging technologies to address DoP 
because the PPPs resolve the market failure associated with DoP research (Glennerster et 
al., 2006). PPPs lower the barrier to entry for drug development, they reduce uncertainty 
in R&D, and they help knowledge flow between the manufacturers and patients. This 
gives incentives for public and private organizations to fund DoP research. 
Unfortunately, there are no studies that examine the relationship between emerging 
technologies and PPP. This dissertation helps scholars better understand the relationship 
between emerging technologies, DOP, and PPPs. 
Research Questions 
There are several different research questions in this dissertation. The first part of 
the dissertation measures the amount of nanomedicine (NM) research that is conducted 
and then assesses inequality in NM research. I use three different measurements to 
understand inequality in NM R&D. First, I test whether NM publications and patents 
have any relation to USA medicine sales. The USA is the biggest market for 
pharmaceutical companies (about 53%) (World Health Organization, 2004), and it drives 




medicine sales relate to NM R&D. I expect that NM research is more likely to address 
diseases with large markets as opposed to small markets.  
Q1.1: Do diseases with high USA medicine sales have more NM R&D than 
diseases with low medicine sales?  
H1.1: High USA medicine sales for a disease are associated with more NM 
publications and patents for that disease. 
The second dimension of health inequality that I investigate is disease burden. 
Disease burden measures the severity of an illness on a population. In order to best 
improve global health, doctors and scientists need to develop medicines that treat 
illnesses with high disease burdens. However, if diseases with small disease burden have 
more NM R&D than diseases with large disease burden, then NM R&D is not greatly 
improving global health inequality, and only a minority of the population are benefitting 
from the technology.  
Similarly, I explore if there is more research on diseases with increasing disease 
burden. I have not found studies that exam the change in disease burden with relation to 
R&D, and as a result, I do not have a good hypothesis of this relationship.  It is possible 
that scientists focus on diseases with increasing disease burden because the diseases are 
more serious and they require greater attention. However, it is also possible that scientists 
study diseases with decreasing disease burden because scientists have developed 
treatments for those illnesses and the areas are viable for research.  
Q1.2: Does disease burden for a specific disease correlate with the amount of NM 
research and development for that disease? Do diseases with growing disease 




H1.2a: Diseases with high burden of disease have more NM publications and 
patents. 
H1.2b: Diseases that have increasing disease burden have more publications and 
patents. 
A third dimension of public health that I investigate is whether diseases of the rich 
are studied more than DoP. If there is less NM R&D for DoP compared to non-DoP, 
holding other factors such as disease burden constant, then NM is increasing health 
inequality.  
Q1.3: Is there less NM research for DoP than other diseases?  
H1.3a: There are fewer NM publications and patents on DoP compared to other 
diseases, controlling for medicine sales and disease burden. 
H1.3b: DoP with more PPP funding (hotdop) have more NM publications and 
patents than other DoP with less PPP funding. 
 After understanding the scale of NM research and inequality, I investigate the role 
that PPPs play in DoP research. As stated before, studies show that PPPs are the most 
important organizations for DoP research (Moran, 2005), and therefore, I expect that 
PPPs will be a major source of NM DoP research.  
Q2: Do formalized PPPs study DOP more than other organizations? 
H2.1: NM DoP research is more likely to be conducted by formalized PPPs than 
other organizations, controlling for variables such as drug sales, disease burden, 
and whether the illness is a disease of poverty. 
As I examined publications and patents, however, I found that fewer than 100 out of 




government agencies conducted most of the NM research. The lack of PPP involvement 
in NM research forced me to shift my attention from studying the importance of PPPs in 
NM research to studying the difference between PPP and NM research. I looked for 
different patterns in the research, partnering organizations, and subject categories.  
H2.2: PPPs’ publications focus on different diseases than NM publications. 
H2.3: PPPs’ publications focus on different fields and sub-disciplines than NM 
publications. 
H2.4: PPPs partner with different organizations than NM researchers.  
I also investigated if PPPs and NM scholars have different integration and specialization 
scores. The integration and specialization scores measure the extent that knowledge is 
being integrated into research. Many scientists believe that research with higher 
integration scores and lower specialization scores are more likely to lead to innovative 
research because this type of research has higher knowledge cross-fertilization across 
disciplines that helps the advancement of science (Hollingsworth, 2008; Moed, Glanzel, 
& Schmoch, 2005; Rafols & Meyer, 2008). Since nanotechnology is a new and emerging 
technology, it should have higher integration scores than other areas of science. Do NM 
publications have higher integration and specialization scores than PPP publications? 
H2.5: PPP publications have lower integration scores than NM publications. 
H2.6: PPP publications have higher specialization scores than NM publications. 
 Finally, the third set of questions examines the factors that influence formal PPP 
funding and research portfolio decisions. How do PPPs decide the types of projects to 
pursue? Do PPPs think NM is a viable field? The goal of these questions is to explain and 




data sources (such as websites and reports) and phone interviews to understand the 
motivations of formal PPPs.  
Data and Methods 
I use both quantitative and qualitative data to study the extent that NM and formal 
PPPs are addressing DoP. For the quantitative analysis, I used publication and patent data 
from Web of Science (WoS), PubMed and PatStat. All three databases are commonly 
used in these types of analyses (Huang, Notten, & Rasters, 2008). From my analysis, 
which is described in more detail in Chapter 3, I found that WoS has about 81,800 NM 
publications and PubMed has about 58,400 PubMed NM publications from 2000-2012. 
PatStat is much smaller than both PubMed and WoS, and it only has about 15,500 NM 
patents from 2000-2009.  
After collecting my bibliometric data, I compare the dependent variables to 
burden of disease, USA medicine sales, and DoP. These data came from the World 
Health Organization (WHO), Bloomberg Finance L.P., Policy Cures and the BioVentures 
for Global Health. I find that only the dummy variable for DoP has any significant impact 
on NM R&D. 
 The qualitative data analysis comes from two sources. First, I analyzed the 
websites of all 28 formal PPPs. Overall, the PPP websites give very detailed descriptions 
of their mission and the importance of the PPP model. Next, I conducted phone 
interviews of PPP managers and scientists. In the interviews, I asked the respondents a 
variety of topics ranging from their research portfolios and patenting practices, to the 




Significance of Study 
This dissertation fills a unique hole in the literature. First, it brings together 
research from three different areas to shed light on the potential for emerging 
technologies to address poverty and inequality. This dissertation impacts public and non-
profit management and contributes to the body of knowledge on PPPs for technology 
development. Over the past 30 years, PPPs have gained prominence; the PPP is now a 
very common organizational structure used for service delivery, policy coordination, 
resource mobilization, and management (Bovaird, 2004). This study specifically looks at 
a new type of PPP that focuses on product development for medicines and vaccines. This 
new type of partnership began forming about 15 years ago, but there are very few studies 
about it (De Pinho Campos, Norman, & Jadad, 2011). Recently, Hanlin et al. examined 
two PPPs, the International AIDS Vaccine Initiative and the Malaria Vaccines Initiative, 
and find that PPPs are important because they act as brokers and knowledge integrators 
as well as play a crucial role in getting technology to poor individuals (Hanlin, Chataway, 
& Smith, 2007). This dissertation extends our knowledge about PPPs by looking at the 
ways they interact with emerging technologies such as NM.  
 Another discipline that this study will push forward is health policy scholarship. 
Currently, there is not a clear understanding of health inequality. Some studies show that 
the gap is widening, especially in sub-Saharan Africa countries (Kilama, 2009), while 
other studies show that the research gap is shrinking (Stevens, 2007). This study will not 
directly solve this controversy, but it does give more insight on inequality within 




 Moreover, the health policy literature is unclear about the connection between 
societal needs and research output for emerging technologies. Many global health 
scholars believe that the lack of R&D for diseases that afflict the poor is one of the 
biggest challenges in public health (Feachem & Sachs, 2002). A 2011 study examines the 
relationship between NIH disease-specific funding and disease burden. The study finds 
that only 33% of the variation in funding can be attributed to disease burden (Gillum et 
al., 2011). Another study by Lichtenberg examines the relationship between disease 
burden and the number of drugs to treat diseases and finds that only disease burden in 
high-income countries affects the number of medicines that are developed (Lichtenberg, 
2005). Similarly, Vanderelst and Speybroeck find that only high-income disease burden 
impacts the number of scientific publications. Low income diseases, even if they have 
large disease burden, do not have a significant impact on drug R&D (Vanderelst & 
Speybroeck, 2013). These studies explain research priorities across science, but they do 
not examine research inequalities in new and emerging technologies. Will 
nanotechnology follow the same trend as science in general, or is there a new pattern of 
research with emerging technologies?  
 Finally, this dissertation will help scholars better understand if scientists are 
developing nanotechnologies that decrease poverty and inequality.  Over the past 15 
years, there has been some hope that nanotechnology could be used to reduce poverty. 
South Africa’s nanotechnology initiative, for example, targets social issues in water, 
energy, and health (Department of Science and Technology South Africa, 2005), and the 
Salamanca-Buentello et al. study finds that there are ten major applications of 




emphasis on using nanotechnology for poverty alleviation should make it more likely that 
nanotechnology will help the poor compared to other technologies, but this hypothesis 
needs to be examined. This study tests whether nanotechnologies are being developed 
that could decrease poverty and inequality.  
Outline of Dissertation 
 This dissertation has six chapters. Chapter 2 discusses the relevant literature 
related to this study. First, I define DoP, and then I give a brief history of PPPs and show 
how they are important organizational structures to address DoP. For this part of the 
literature review, I draw on literature from new public management, management, and 
health policy. Next, I use the science and innovation policy literature to describe 
emerging technologies and compare nanotechnology to the current definition of emerging 
technology. I conclude that nanotechnology is a good example of an emerging 
technology and that it is an important technology to examine research inequality.  
 Chapter 3 describes the data and methods used in the dissertation. I use data from 
WoS, PubMed, PatStat, Bloomberg Finance L.P., and the WHO. The mixed-method 
approach employs negative binomial Poisson regression analysis, website content 
analysis, and semi-structured interviews of scientists and PPP managers.  
 Chapters 4 and 5 discuss the research findings. Chapter 4 focuses on the findings 
from the quantitative data while Chapter 5 gives the results from the qualitative data. In 
these chapters, I specifically address whether the hypotheses were rejected or accepted. I 
also discuss other findings that were not part of my original hypotheses. Finally, in 








The goal of this chapter is to give a brief overview of the literature and 
intellectual foundations of the dissertation. This study measures the amount of inequality 
in NM research and the role of formal PPPs in addressing the research imbalance. To 
understand these questions, I begin by reviewing the literature on global public health and 
DoP. I discuss the definitions of public goods, public health, and DoP; I then provide the 
reasons why a health research gap arose. Next, I review the literature on PPPs. PPPs are 
the most prominent institutions doing research on DoP (Moran et al., 2010), and the 
literature review explains the purpose of PPPs and how these organizations address many 
of the market failures associated with DoP. The PPP literature is a convergence of several 
disciplines; however, I focus the literature review on the definition of PPP, as well as on 
the role of PPP in the public management and public policy fields.  
 The third section of this chapter gives background on emerging technologies and 
NM. The term “emerging technology” is a buzzword that is often used to describe new 
technologies, but the term it is not clearly operationalized. Cozzens et al. give four 
characteristics of emerging technologies, and from their definition I show that 
nanotechnology is a good example of an emerging technology (Cozzens et al., 2010). 
Finally, I highlight previous studies on medical research inequality and DoP. These 
studies examine the relationship between disease burden, research output, and 




are no studies that specifically analyze research inequality in NM or the role of PPP in 
R&D for emerging technologies.  
Global Health and Diseases of Poverty 
Doctors have treated patients for centuries, and governments have always been 
concerned with outbreaks of diseases. However, with the rise of rapid global 
transportation during the 1800s, government officials had a new impetuous to solve 
global health problems because the diseases could easily spread to new populations (Birn, 
2009). Today, improving global health is still one of the major public goods that concern 
the world community.  
A pure public good has two qualities; it is non-rivalrous and non-exclusive 
(Feachem & Sachs, 2002). Health, therefore, is not considered a public good by most 
economists because it is very exclusive. Only an individual feels the benefits of good 
health, and others cannot share in the benefits of someone else’s health. However, public 
health is argued to be a public good because when health is viewed as an aggregate good, 
then public health is non-rivalrous and non-exclusive (Feachem & Sachs, 2002). If a 
country has a healthy population, then the whole nation benefits from the low risks of 
disease and illness.  
A major focus of global public health is addressing the global public good of 
improving the health of the poor and eliminating many DoP. A disease of poverty is a 
disease that predominantly affects the poor. The WHO Special Programme for Research 
and Training in Tropical Diseases (WHO-TDR) defines DoP as “diseases that affect 
mostly the poor in developing countries” (World Health Organization, 2010a). The WHO 




tuberculosis. These diseases receive the most attention from the global community, and 
there is significant investment in eradicating them (World Health Organization, 2010a). It 
is estimated that 63% of DoP drug development is for the “big three” DoP (Ponder, 
2012). The other diseases that the WHO classifies as DoP are neglected tropical diseases 
(NTD). There are 17 NTD, and these diseases, which are “a proxy for poverty and 
disadvantage, affect populations with low visibility and little political voice; [These 
diseases] do not travel widely; cause stigma and discrimination, especially among girls 
and women; have important impact on morbidity and mortality; are relatively neglected 
by research; [and] can be controlled, prevented, and possibly eliminated using effective 
and feasible solutions” (World Health Organization, 2010b).   
In addition to the “big three” and NTD, BIO Ventures for Global Health, a non-
profit that specializes in accelerating research on medicines for developing countries, 
classifies diseases such as diarrheal diseases, cholera, and typhoid fever, as DoP (Ponder, 
2012). Policy Cures, another health nonprofit, lists 31 neglected diseases. This nonprofit 
considers an illness a disease of poverty if it meets three conditions: “the disease 
disproportionately affects people in developing countries, there is a need for a new 
products, [and] there is a market failure” (Moran et al., 2010). Table 1 lists the DoP 





TABLE 1 LIST OF DISEASES OF POVERTY 
“Big Three” 
Diseases  Neglected Tropical Diseases Other Diseases of Poverty 
Tuberculosis Buruli Ulcer  Leprosy  Podoconiosis  Typhoid Fever  
HIV/AIDS Chagas disease Lymphatic filariasis  Snakebite  Pneumococcal 
Disease  
Malaria Cysticercosis  Onchocerciasis  Strongyloidiasis Cryptosporidium 
  Dengue/Severe dengue  Schistosomiasis  Diarrheal Disease EAggEC 
  Dracunculiasis (guinea-
worm)  
Sleeping Sickness Cholera  Giardia 
  Echinococcosis  Soil transmitted 
helminthiasis  
ETEC  Roundworm 
  Fascioliasis  Trachoma  Rotavirus  Hookworm 
  Human African 
Trypanosomiasis  
Yaws  Shigellosis  Whipworm 
  Leishmaniasis    Salmonella 
infections  
Rheumatic Fever 
Causes of Diseases of Poverty 
In general, scholars believe that DoP arise from two market failures. First, the 
market fails to account for the negative externalities associated with DoP. The 
pharmaceutical companies focus their attention on medicines that will generate large 
profits and fail to do R&D on illnesses that mainly affect poorer populations and have 
large negative externalities. For example, diseases from developing countries can easily 
spread to other parts of the world, and by neglecting DoP, the world community puts 
itself at risk of spreading the disease (Kremer, 2002).  
A second market failure associated with DoP is that there is a time-inconsistency 
problem for pharmaceutical companies. To produce medicines for DoP requires a large 
initial investment in R&D, but once the drug companies produce the medicines, the 
customers “have every incentive to use their powers as dominant purchasers to keep 
prices down to maximize access to these life-saving products” (Berndt & Hurvitz, 2005). 




market can demand a lower cost once the medicine has been produced. This leads to 
many neglected illnesses. 
Not all scholars think that DoP pose a serious risk. Stevens argues that labeling 
neglected diseases as a serious public health concern is unnecessary because many 
neglected diseases have effective medicines (Stevens, 2007). He writes that most DoP 
have drugs in the pipeline or effective treatments that are currently available. For 
example, rotavirus has four vaccines in the pipeline, and yaws, a bacterial infection that 
affects bone and cartilage, already has effective medicines on the market (Ponder, 2012). 
 In addition, Stevens points out that many neglected diseases do not pose the 
greatest health risk to individuals in developing countries. For example, in 2004, the 
neglected disease Chagas only caused of 3,000 disability adjusted life years (DALYs) in 
low income countries while road accidents caused 16.7 million DALYs (World Health 
Organization, 2008). Rather than focusing on diseases that affect only a few people, 
Stevens suggests the world community could concentrate on issues such as road accidents 
that have bigger impacts on global health. 
Finally, Stevens argues that the research gap is irrelevant because diseases of the 
rich and poor are converging (Stevens, 2007). Cardiovascular disease and other lifestyle 
diseases are quickly becoming the most serious illnesses in developing countries. 
Therefore, the need for research on DoP is not as relevant as research on lifestyle 
illnesses.  
Public-Private Partnerships 
For hundreds of years, governments have partnered with private organizations. An 




of the Netherlands with the Dutch East India Company. The Dutch East India Company 
was a private sector company, yet it was an agent of the Netherlands and often performed 
government functions such as negotiating treaties, coining money, and governing the 
colonies. During WWII, governments relied heavily on the private industry for the war 
movement, and after the war, the private sector was crucial for international development 
(Hounshell, 1992). Despite the long history of the public and private sectors working 
together, the term “public-private partnership” was first used about 40 years ago. Since 
then, the phrase has grown in prominence, and now it is widely used by politicians, 
businesspeople, and non-profit organizations (Bovaird, 2004).  
 However, many scholars debate whether PPPs are a new phenomenon or simply a 
relabeling of old organizational patterns that have been around for a long time (Graeme 
A. Hodge, 2010). The scholars who believe that PPPs are not a new phenomenon say that 
individuals only use the term PPP because it has positive connotations compared to 
phrases such as privatization and outsourcing. Instead of a politician saying that the 
government will “privatize industries,” they prefer to discuss “partnering with industry 
and civil society organizations” (Hodge, 2009; Khanom, 2010). In response to these 
criticisms, other scholars counter that the current structure and emphasis of PPPs is a new 
phenomenon. In the past twenty years, dozens of governments established PPP agencies 
and these partnerships are working in new areas such as vaccine development and clinical 
trials (Farrugia, Reynolds, & Orr, 2008).  
PPP scholarship comes from several academic disciplines. First, many scholars 
view PPPs as stemming from neoliberal economics and new public management. 




market forces can be the main mode for change. These theories believe that the private 
sector can allocate resources more efficiently than the public sector, and as a result, there 
is a push towards privatization of government services and deregulating industries in 
order to give them more freedom to operate (Bovaird, 2004; Miraftab, 2004). According 
to neoliberal economics and new public management, PPPs are the conduit for the 
government to privatize many services.  
Another field that PPP scholarship draws from is economics and game theory. In 
game theory, cooperation helps individuals pursue their own self-interests (McQuaid, 
2000), and as a result, partnerships arise to help an individual achieve a higher utility. 
PPPs are one type of cooperation that helps two organizations achieve a more positive 
outcome.  
Similarly, in the public administration and management literature, scholars 
discuss the importance of interorganizational relationships (IOR) because networks and 
connectedness are essential for the survival and performance of organizations (Khanom, 
2010; Oliver, 1990). One definition of IOR is “relatively enduring transactions, flows, 
and linkages that occur among or between an organization and one or more organizations 
in its environment” (Oliver, 1990). PPPs can be considered a subset of IOR (Edelenbos & 
Klijn, 2007). The management literature also describes PPPs as cross-sector partnerships 
(Selsky & Parker, 2005) and joint partnership (Hall, 1991, p. 219).  
Definition of Public Private Partnership 
One heavily cited definition of a PPP is “working arrangements based on a mutual 
commitment (over and above that implied in any contract) between a public sector 




definition is broad, and it allows PPPs to be between a government entity and any non-
government entity such as a company, nonprofit organization, or local community group. 
A key part of Bovaird’s definition is that the mutual commitment between 
organizations has to be “over and beyond that implied by a normal contract”(Bovaird, 
2004). Bovaird does not expound upon the level of interaction necessary to be classified 
as “over and beyond” a normal contract, but he suggests that the firms must make a 
commitment for a close and ongoing relationship that is not based purely on a monetary 
transactions or monitoring/ enforcement agreements (Bovaird, 2004). In a normal 
government contract, the government sets the boundaries of the project and acts as the 
principal that watches over the agents as they complete a task. In essence, “the 
Government acts as commissioning party, lays down the characteristics of the project and 
contracts out the construction and exploitation to a private contractor on the basis of a 
clear-cut and straightforward programme of requirements” (Van Ham & Koppenjan, 
2001). Contract-based government relationships have led to a “hollow state” in which the 
government uses third parties to provide public services (Milward & Provan, 2000). This 
type of relationship is not a partnership but rather normal government interaction with the 
private sector.  
Some criticize Bovaird’s broad definition of PPPs because it makes it difficult to 
understand how PPPs operate, and it hides underlying power distributions within them. 
PPPs do not necessarily consist of equally powerful organizations; rather, there is a wide 
range of power and resource distribution within PPPs (McQuaid, 2000; Miraftab, 2004). 
For example, a PPP could be between a strong government agency and a weak civil 




government directive. One scholar says that “the terminology sloppiness in debates about 
PPPs fosters convenient ambiguities in defining the roles and expectation of each 
partner” (Miraftab, 2004). As a result, I narrow the types of PPPs for this study to formal 
public-private partnerships (see the next section for a more thorough discussion of formal 
PPPs). 
The literature gives a number of reasons that public-partnerships form. First, as 
the world gets more complex, a single organization does not have the resources and 
knowledge to solve problems, and so in order to accomplish their goals, organizations 
partner together (McQuaid, 2000; Van Ham & Koppenjan, 2001). This reason for 
establishing partnership is especially relevant when examining emerging technologies. 
Emerging technologies are at the forefront of knowledge, and a variety of sectors must 
work together to develop the technology (Cozzens et al., 2010). PPPs help transfer 
knowledge between organizations and sectors. A classic example of multiple 
stakeholders working together to develop an emerging technology occurred with the 
personal computer. Throughout the twentieth century, government labs, universities, and 
companies were all involved in developing computers (Bovaird, 2004). They set 
standards, designed manufacturing processes, and set the pace for the improvements in 
microprocessing technology.  
A second reason that organizations form PPPs is that a group of organizations are 
better at overcoming market deficiencies than a single actor (McQuaid, 2000; Van Ham 
& Koppenjan, 2001). For example, some innovations have high technical risk that 
prevent them from being economically attractive, and other innovations have low 




spreading the risks of failure over multiple parties and projects, so that they will have 
limited exposure and liability (Greve, 2006). Partnerships also improve the economies of 
scale and increase the scope of the individual organization (Bovaird, 2004). Most health 
R&D PPPs have expert scientific boards from different sectors that help them make 
prudent decisions about research portfolios. PPPs can also pool resources from several 
sources and invest in multiple projects at once. In contrast, smaller organizations do not 
have the personnel and financial resources to work on multiple projects simultaneously 
(Moran et al., 2010).  
Finally, PPPs build new organizational structures “capable of generating new 
technologies” (Chataway et al., 2010) and new social interactions (Chataway, Tait, & 
Wield, 2007). These new structures give these organizations more legitimacy to operate, 
allow them to have a greater impact, and brings together techniques and ideas from 
different sectors (McQuaid, 2000; Selsky & Parker, 2005).  
However, not all scholars think that PPPs are beneficial for development. 
Miraftab describes PPPs as Trojan Horses because they can hide unequal power 
relationships that lead to the community partners being marginalized by the dominant 
partner. In low-income countries, often the agendas of foreign governments and 
researchers take priority because those entities have the money and influence to direct the 
PPP (Miraftab, 2004). Rather than thinking of PPPs as a panacea to problems, Miraftab 
suggests that PPPs focus on social, economic and cultural conditions (Miraftab, 2004). 




Types of Partnerships 
There are several typologies to describe the different variations of PPPs. One 
typology proposed by Brinkerhoff characterizes PPPs on two dimensions: mutuality and 
organizational identity. Brinkerhoff recognizes that partnerships fall on a continuum 
ranging from simple contracts to full PPPs. Brinkerhoff believes that only organizations 
that have high mutuality and organizational identity are PPPs (J. M. Brinkerhoff, 2002). 
Another typology of partnerships focuses on the particular sectors involved in the 
partnership and whether the partnership solves a resource dependence problem or shares 
a similar social platform (Selsky & Parker, 2005). Moreover, scholars describe the 
various purposes of PPPs. They can do policy design, policy evaluation and monitoring, 
implementation, capacity building, activism, and resource mobilization (Bovaird, 2004; 
D. W. Brinkerhoff & Brinkerhoff, 2011). They can also help with innovation by 
increasing the cooperation and knowledge linkages between organizations.  
Due to the broad range of PPPs and their functions, this dissertation will focus on 
a subset of PPPs called formal PPPs. Based on the definition of PPP by Hanlin et al., I 
define formal a public-private partnership as a partnership between government and non-
government organizations that is operationally and legally independent from the 
collaborating organizations after it is formed (Hanlin et al., 2007). In these PPPs, several 
public and private organizations join together to start a separate non-profit entity. Formal 
PPPs are a good unit of analysis because they are easy to identify. Most formal PPPs 
identify themselves as PPPs, and they give information about their structure. Also, there 
is a growing body of literature that discusses formal PPPs and how they operate. For 




maintain a database of funding flows to and from these organizations (Moran et al., 
2010). Finally, formal PPPs are very active in DoP research, so it is important to study 
them.  
An example of a formal PPP is a product development partnership (PDP). PDPs 
gained prominence as organizations that conduct disease of poverty R&D (Moran et al., 
2010). Chataway et al. defines PDPs as “a technology push initiative aimed at providing 
new science and technology based products for neglected diseases” (Chataway, Hanlin, 
Muraguri, & Wamae, 2009). Moran estimates that in 2004, 75% of R&D projects for 
neglected diseases were conducted by PDPs (Moran, 2005), and that 14 PDPs spent $262 
million on neglected disease R&D in 2007 (Moran et al., 2010). Two prominent formal 
PPPs conducting research on DoP are the International Aids Vaccine Initiative and the 
Malaria Vaccine Initiative.  
Emerging Technologies  
Another topic this dissertation explores is the role of emerging technologies to 
address poverty and inequality. In the literature, there is no clear definition of emerging 
technology; the term is rarely operationalized, and it is used across disciplines without a 
clear academic basis (Cozzens et al., 2010; Veletsianos, 2010). The term emerging 
technologies first appeared in the literature in the 1960s and became more widely used in 
the 1990s (Cozzens et al., 2010); however, the concept of an emerging technology has a 
longer history. Kondratieff discusses the “long waves of technical change”, and 
Schumpeter writes about creative destruction (Avila-Robinson & Miyazaki, 2011). Both 




As stated before, there is no clear definition of emerging technology; however, 
when the various definitions are systematically analyzed, there are four main 
characteristics of emerging technologies (Cozzens et al., 2010). First, emerging 
technologies are characterized by fast and recent growth (Cozzens et al., 2010). If the 
technology languishes for a long time or it has a slow adoption then it is not an emerging 
technology. The second characteristic of emerging technologies is that it is a transition or 
change to something new (Cozzens et al., 2010). Like fast growth, novelty is an 
important aspect of emerging technologies. The third characteristic of emerging 
technology is that it has an economic or market potential (Cozzens et al., 2010). Even if 
an innovation is a superior technology than a previous product, it is not considered an 
emerging technology unless it has market potential. Finally, emerging technologies must 
be based on scientific innovation or breakthrough. There are many innovations that are 
important, but they are not based on scientific breakthroughs, and as a result, they are not 
considered an emerging technology (Cozzens et al., 2010). For example, there are 
organizational innovations, such as the assembly line, that are important innovations but 
not based on scientific breakthroughs. As a result, those technologies are not considered 
emerging technologies.  
Nanotechnology  
One technology that has received a lot of attention as an emerging technology is 
nanotechnology (Youtie, Iacopetta, & Graham, 2008). Nanotechnology is “science, 
engineering, and technology conducted at the nanoscale, which is about 1nm-100nm” 
(nano.gov). At the nanoscale, matter has different properties, such as conductivity, color, 




people think the novel properties of nanoscale materials will transform science and 
engineering. One scientist said that nanotechnology could be as transformational as “the 
steam engine in the 18th century, electricity in the 20th century, and the Internet in 
contemporary society”(Hassan, 2005). Because of the large potential of nanotechnology, 
significant investments have been made in the field. In 2000, the USA established the 
National Nanotechnology Initiative with an initial funding of $475 million. That funding 
level has steadily grown and in 2013 the NNI received $1.8 billion dollars (nano.gov). 
Europe and China have made similar large investments in nanotechnology. By 2004, 
about 62 countries had some type of nanotechnology initiative (Maclurcan, 2010a). 
The excitement about nanotechnology is not only in rich countries. There is 
emphasis on nanotechnology R&D centers in low-income countries, and several 
developing nations started nanotechnology initiatives. Many scientists believe that 
nanotechnology can have major benefits for poor and marginalized communities, and that 
nanotechnology research in low-income countries is essential for creating context-
specific technologies (Singer, Salamanca-Buentello, & Daar, 2005). Some believe that if 
low-income countries do not conduct nanotechnology R&D, then the nanotechnology 
revolution will pass them by. In one study, researchers asked nanotechnology experts 
which nanotechnologies could have the greatest benefit for developing countries. The 
scientists responded with applications that ranged from improved solar cells to cheaper 
construction materials (Salamanca-Buentello et al., 2005).  
Nanotechnology as an Emerging Technology 
As stated before there are four qualities of emerging technology: fast recent 




increasing science-based-ness. Nanotechnology fits all the definitions of emerging 
technology, and hence, it is a good case to use in this dissertation. The principles taken 
from the nanotechnology case can then be generalized to other emerging technologies 
that also follow a similar development path as nanotechnology. 
The first characteristic of emerging technology is that it has fast recent growth. 
Throughout the 2000s, nanotechnology saw immense R&D. It is estimated that in 1990, 
there were about 2000 nanotechnology publications and 400 nanotechnology patents. By 
2005, there were about 56,000 nanotechnology articles in WoS and 12,200 
nanotechnology patents in MicroData and International Patent Documentation Center 
(INPADOC). Moreover, the number of country nanotechnology programs went from 0 in 
1999 to 62 by 2004 (Maclurcan, 2010a).  
The second characteristic of emerging technologies, a transition/change to 
something new, has been debated within the nanotechnology literature. Some scientists 
argue that working at the nanoscale is not new; rather, chemists have operated at the 
nano-level for centuries. For example, the Romans used gold and silver nanoparticles in 
paint pigments for glass (Maclurcan, 2005). Also, sol-gel processes (a method of making 
solid substance from small particles), which were first used in the 1800s, contain 
nanoparticles (Baer, Burrows, & El-Azab, 2003; Hench & West, 1990). Moreover, in 
personal interviews, scientists often say that nanotechnology is just a buzzword and that 
although it is interesting, it is not new. Despite the criticism, nanotechnology research has 
some features that are different from older scientific traditions. Nanotechnology 
researchers use new equipment, such as scanning electron microscopes, which allows 




capabilities to build nano devices from the “bottom up” as opposed to relying strictly on 
top-down processes. Finally, although chemistry and other processes operate at the 
nanoscale, current researchers have a certain level of precision that allow scientists to 
actually manipulate individual atoms and molecules (Maclurcan, 2005).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
The third reason that nanotechnology is an emerging technology is because it is 
estimated that nanotechnology products will have a large market. Early in the 2000s, 
experts predicted that nano-enabled products could have a market of more than $2 trillion 
by 2015 (Berger, 2007). Currently, there are over 1,300 nano-enabled products on the 
market, ranging from lip balm to water recreation vehicles (Woodrow Wilson 
International Center, 2012).  
Finally, nanotechnology is a science-based technology. A variety of fields such as 
chemistry, physics, and material science make up the field of nanotechnology. The 
scientific nature of nanotechnology is evident in the number of Nobel Prizes 
nanotechnology scientists have received. In 1996, Robert Curl, Harold Kroto, and 
Richard Smalley won the Nobel Prize in chemistry for “discovering” the fullerene, a 
nanoparticle. Later, in 2007, Albert Fert and Peter Grunberg won the Nobel Prize in 
Physics for research on magnetism and resistance at the nano-scale. Most recently, in 
2010, another Nobel Prize in Physics was awarded to Andre Geim and Konstantin 
Novoselov for making graphene, another nano material (“Nobelprize.org,” 2012).  
Nanomedicine 
 A large portion of the nanotechnology field is focused on medical applications. 
NM has roots back to Richard Feynman, who is often identified as the father of 




Feynman describes a future where little robots are surgeons inside the body. He predicted 
that one day, doctors could “put the mechanical surgeon inside the blood vessel and it 
goes into the heart and ‘looks’ around….It finds out which valve is the faulty one and 
takes a little knife and slices it out. Other small machines might be permanently 
incorporated in the body to assist some inadequately functioning organ” (Feynman, 
1959). Today, we are not close to realizing Feynman’s dream of surgeons in the body, but 
scientists are designing cheap and more sensitive diagnostics tools, novel drug delivery 
systems, and implants/prosthetics (Freitas, 2005; Guo, Zhou, Porter, & Robinson, 2014). 
Despite the major efforts of scientists and funding agencies to use nanotechnology 
to address healthcare needs, one criticism is that nanotechnology may not be the best tool 
to fix health problems (Invernizzi, 2006). Some will argue that genes, hormones, and 
proteins may hold the key to new medicines and that nanotechnology is not as important. 
Also, many of the DoP already have viable prevention and treatment options, but these 
diseases remain a problem due to social factors rather than the lack of medicines and 
vaccines (Invernizzi, 2006). Therefore, a technical solution, such as nanotechnology, will 
not be able to solve the problems.  
In response to these criticisms, scholars note that NM is a broad platform 
technology and can be incorporated into a plethora of medicines (Best & Khushf, 2006; 
Freitas, 2005). As a result, it will work alongside other health research that focuses on 
genes and hormones. Moreover, as drug resistance grows for many common medicines, 
NM can serve as a platform to create resistance free medicines and vaccines (Santos-
Magalhães & Mosqueira, 2010). Finally, the worry that nanotechnology is irrelevant for 




Salamanca-Buentello et al. study, three of the top ten poverty-alleviating 
nanotechnologies relate to NM (Salamanca-Buentello et al., 2005).  
Other Studies 
 Over the past ten years, more scholars have tried to understand the gap in health 
care research and the impacts of disease burden on research priorities. In 2005, 
Lictchenberg studied the relationship between disease burden and pharmaceutical 
innovation. He operationalizes pharmaceutical innovation by counting the number of 
drugs that were developed to treat a particular disease and the number of new drugs 
launched around the world. He finds that “pharmaceutical innovation is positively related 
to the burden of disease in developed countries but not to the burden of disease in 
developing countries” (Lichtenberg, 2005). He reasons that the gap in pharmaceutical 
innovation occurs because there are few incentives for pharmaceutical companies to 
manufacture drugs for the poor (Lichtenberg, 2005).  
In 2011, Gillum et al. examined the relationship between the NIH disease funding 
and disease burden with other variables such as public interest, charity funding, and 
disease-specific articles in PubMed. The NIH is the largest sponsor of biomedical 
research, and their research priorities have major impacts on R&D. Gillum et al. find that 
the most significant factor in determining NIH funding levels is the burden of disease 
(Gillum et al., 2011), while other factors such as public interest and charity revenue have 
a significant yet smaller effect on NIH funding.  
Another study by Vanderelst and Speybroeck examines the relationship between 
disease burden and publications. They show that funding level is correlated with research 




publications on that disease. Next, they examine how disease burden affects research 
funding. They find that diseases that predominantly affect high-income countries drive 
research priorities and that high income diseases tend to be overfunded relative to their 
disease burden (Vanderelst & Speybroeck, 2013).  
Other studies examine the role that nanotechnology could have on reducing 
poverty. First, many studies question whether nanotechnology can decrease inequality 
and poverty. Cozzens et al. examine nanotechnology in the energy, water, and agri-food 
sectors. The authors find that there is some work on nanotechnologies that could benefit 
the poor, but the socio-technical system of many poor countries does not match the 
technology that was developed (S. Cozzens et al., 2013). Another study by Invernizzi 
discusses the role that nanotechnology will have on employment. She predicts that 
nanotechnology could increase inequality because many middle wage jobs will be 
destroyed by the nanotechnology revolution (Invernizzi, 2011).  
Finally, there have been some bibliometric studies on NM (Chen & Guan, 2011; 
Wagner, Dullaart, Bock, & Zweck, 2006). These papers give a general overview of 
global NM trends, and they find that NM publications have grown exponentially grown 
over the past ten years. Chen & Guan go on to show that the USA, Germany, France, and 
Italy are world leaders in NM. China is a latecomer to NM research, but it is quickly 
growing in importance (Chen & Guan, 2011).  
Conclusion 
 This dissertation draws upon disparate sources of knowledge in order to 
understand new phenomena. Nanotechnology has been hailed as an emerging technology 




tested. This dissertation measures research inequality in NM and the role of PPPs in R&D 
for new medicines and vaccines. I use literature from a variety of disciplines, such as 
public administration, public health, and science policy. The public administration 
literature gives a foundation for my investigation of PPPs, and the public health literature 
helps me analyze DoP. From there, I add information about emerging technologies and 
nanotechnology from science policy. The next chapter reviews the data and methods of 





CHAPTER 3: DATA SOURCES AND METHODS 
 
Introduction 
 Scholars believe PPPs are necessary to develop medicines for DoP (Reich, 2000). 
Scholars reason that DoP do not have a large market and that pharmaceutical companies 
have little incentive to develop drugs for these illnesses since they will be unable to 
recoup research expenditures. As a result, governments, companies, and nonprofit 
organizations must partner together to develop medicines for these diseases.  
In this dissertation, I analyze the extent of NM research for DoP and the role PPPs 
play in that research. For this analysis, I use secondary data analysis, bibliometrics, 
website content analysis, and interviews. The secondary data and the bibliometrics are 
used in the quantitative data analysis and the data comes from the WHO, Policy Cures, 
Bloomberg Finance L.P., the Institute for Health Metrics and Evaluation (IHME), WoS, 
PatStat, and PubMed. The website content analysis and interviews of scientists and PPP 
managers are used to inform the quantitative data and to describe the role of PPPs in DoP 
research.  
 In this chapter, I discuss the data collection methods and how I cleaned and 
analyzed the quantitative and qualitative data. I used a software program called 
VantagePoint to manipulate, clean and sort the bibliometric data, and then I used Stata 
and Excel to merge the data and statistically analyze it. For the website content analysis 





Data for Independent Variables 
WHO and IMHE 
 In 2008, the WHO released statistics on the global burden of disease. The data 
gives information on BoD based on age, gender, and county income level. Later, IMHE 
released updated BoD estimation for 1990, 2005, and 2010. In this analysis, BoD is one 
of the major independent variables used to understand the relationship between BoD and 
NM publications and patents.  
 The 2008 WHO BoD dataset contains 136 diseases/injuries, and the updated 
IMHE dataset contains BoD data on 291 diseases/injuries and 1160 disease sequelae. The 
data has a variety of demographic information such as age, world region, and gender. 
Table 2 lists all the diseases used in the analysis. It contains all the illnesses from the 
2008 WHO dataset, but excludes BoD statistics from injuries such as falls, automobile 




TABLE 2 LIST OF DISEASES USED IN THE ANALYSIS (*= DISEASE OF POVERTY) 
Abortion Hypertensive disorders Other musculoskeletal disorders 
Alcohol use disorders Hypertensive heart disease Other neoplasms 
Alzheimer and other dementias Inflammatory heart disease  other neuropsychiatric diseases 
Appendicitis Insomnia (primary) other oral diseases 
Ascariasis (roundworm)* Intestinal nematode infections* Other respiratory diseases 
Asthma Iodine deficiency Otitis media 
Benign prostatic hypertrophy Iron-deficiency anemia Ovary cancer 
Bipolar affective disorder Ischemic heart disease Pancreas cancer 
Birth asphyxia and birth trauma Japanese encephalitis* Panic disorder 
Bladder cancer Leishmaniasis* Parkinson disease 
Breast cancer Leprosy* Peptic ulcer disease 
Buruli ulcer* Leukemia Perinatal conditions* 
Cardiovascular diseases Liver cancer (hepatic cancer) Periodontal disease 
Cataracts Lower back pain Pertussis* 
Cerebrovascular disease Lower respiratory infect. (pneumonia)* Pneumonia* 
Cervix uteri cancer Lymphatic filariasis* Poliomyelitis 
Chagas disease* Lymphomas, multiple myeloma Post-traumatic stress disorder 
Chlamydia Macular degeneration and other Prematurity and low birth weight 
Cholera* Malaria* Prostate cancer 
Chronic obstructive pulmonary dis. Malignant neoplasms Protein-energy malnutrition 
Cirrhosis of the liver Maternal conditions Refractive errors 
Colon/rectum cancer Maternal hemorrhage Respiratory diseases 
Congenital abnormalities Maternal sepsis Respiratory infections 
Corpus uteri cancer Measles Rheumatic heart disease 
Cysticercosis* Melanoma and other skin cancers Rheumatoid arthritis 
Dengue* Meningitis Rotavirus* 
Dental caries mental retardation, lead-caused Salmonella enterica* 
Diabetes mellitus Migraine Salmonella Infection* 
Diarrheal diseases* Mouth and oropharynx cancers Schistosomiasis* 
Digestive diseases Multiple sclerosis Schizophrenia 
Diphtheria Musculoskeletal diseases Sense organ disorders 
Drug use disorders Neonatal infect. and other conditions* Shigellosis* 
Dysentery Nephritis/nephrosis Skin diseases 
eaGGec* Neuropsychiatric disorders STDs excluding HIV 
Echinococcosis* Noncommunicable conditions Stomach cancer 
Edentulism Nutritional deficiencies Syphilis 
Epilepsy Nutritional/endocrine disorders Tetanus 
ETEC* Obsessive-compulsive disorder Trachea/bronchus/lung cancers 
Fascioliasis* Obstructed labor Trachoma* 
Giardiasis* Oesophagus cancer Trichuriasis (whipworm)* 
Glaucoma Onchocerciasis* Trypanosomiasis* 
Gonorrhoea Oral diseases Tuberculosis* 
Gout Osteoarthritis Typhoid fever* 
Hearing loss, adult onset Other cardiovascular diseases Unipolar depressive disorders 
Hepatitis B Other digestive diseases Upper respiratory infections 
Hepatitis C Other genitourinary system diseases Vitamin A deficiency 
HIV/AIDS* other malignant neoplasm Yaws* 




One key independent variable I use in the analysis is disability adjusted life years 
(DALY). A DALY is a measure of BoD1, and it equals years of life lost (YLL) plus years 
lost due to disability (YLD). See Equation 1 for mathematical explanation.  
EQUATION 1 DISABILITY ADJUSTED LIFE YEARS CALCULATION 
 
 
(Cooper, Osotimehin, Kaufman, & Forrester, 1998) 
 
DALYs are a good measure of disease burden because they include both mortality 
rates and disability due to disease. There are several diseases that are highly disabling yet 
have low morality rates. If disease burden is only measured by mortality rates, then the 
impact of chronic disease on a person’s wellbeing is underestimated. Another reason I 
use DALYs in this analysis is that it is a standard measure for disease burden (Murray et 
al., 2012), which makes it easier to compare my results with previous studies. Finally, 
DALY data is free, and it is one of the few health statistics with reliable global coverage.   
 Even though DALYs are a standard measure for disease burden, it has been 
criticized. Some scholars comment that DALYs are inaccurate because there is not 
enough information to generate DALY measurements for some diseases and countries.   
The extrapolation that scientists use to generate DALYs overestimates the severity of 
some diseases and discounts the importance of others. For example, one study estimates 
                                                          
1 Another common measure used in health evaluations is quality adjusted life years (QALY). A QALY 
measures the health gains due to interventions (Mathers, Ezzati, & Lopez, 2007). DALYs and QALYs are 
calculated differently, and as a result, they emphasize different facets of health. Health professionals desire 
to maximize QALY and minimize DALYs (Gold, Stevenson, & Fryback, 2002). Since I am concerned with 




that DALYs underestimate ischemic heart disease by 27% due to a lack of accurate health 
records (Cooper, Osotimehin, Kaufman, & Forrester, 1998). Another criticism is that 
DALYs disadvantage the poor and those with less access to resources. A blind person in 
a poor country would face very different struggles than a blind person in a rich country; 
however, they would each have the same DALY. Similarly, some believe that disability 
weight assignments should not be constant across individuals. Even in the same country, 
individuals experience disabilities differently, and it is difficult to compare the pain 
across individuals (Anand & Hanson, 1997). Despite these criticisms, DALYs are one of 




Table 3 is an illustrative list of burden of disease measurements in DALYs. 
 In the analysis, there are two variables related to DALYs. First, I use the updated 
IHME 2010 DALYs (bod2010) to measure the disease burden. Secondly, I create a 
variable called increase to measure the difference in disease burden between 2005 and 
2010. This variable will help me determine if scientists are focusing more on diseases 
that have an increasing or decreasing disease burden. Currently, there is no research that 
examines the change in disease burden in relation to R&D; as a result, this variable will 






TABLE 3 DISEASES WITH HIGHEST WORLDWIDE DALY IN 2010 
Disease DALY %Total 
Ischemic heart disease 129,819,898 5.2 
Low back pain 83,063,498 3.3 
Malaria 82,685,191 3.3 
Preterm birth complications 76,981,719 3.1 
Chronic obstructive pulmonary disease 76,731,358 3.1 
HIV/AIDS 66,599,553 2.7 
Major depressive disorder 63,179,254 2.5 
Hemorrhagic and other non-ischemic stroke 62,842,897 2.5 
Neonatal encephalopathy  50,149,575 2 
Tuberculosis 49,396,246 2 
Diabetes mellitus 46,823,256 1.9 
Iron-deficiency anemia 45,338,235 1.8 
Sepsis and other infectious disorders of newborn baby 44,236,491 1.8 
Ischemic stroke 39,389,407 1.6 
Self-harm 36,654,294 1.5 
Falls 35,385,079 1.4 
Protein-energy malnutrition 34,874,497 1.4 
Neck pain 33,640,233 1.3 
Trachea, bronchus, and lung cancers 32,404,655 1.3 
 
 
Diseases of Poverty 
  DoP are diseases that predominantly affect the poor. I compiled a list of DoP 
from three organizations: the WHO, BioVentures for Global Health, and Policy Cures. In 
Table 2, the diseases marked with a * are DoP. In this analysis, I test whether there is 
more NM research for non-DoP than DoP. In the regression analysis, I use a dummy 
variable dop to represent DoP. For more information on DoP, see Chapter 2.  
G-FINDER 
The Global Funding of Innovation for Neglected Diseases (G-FINDER) database 
is a free online database that contains funding information for 31 neglected diseases from 
over 50 countries and 240 organizations. For the past five years, Policy Cures, the 




understand the global flow of funding and resources for DoP R&D (Moran et al., 2011). 
The G-FINDER database contains data on a variety of metrics such as DoP R&D funding 
by disease, recipient organization, year, type of funding organization, and country. In the 
analysis, I use a variable called hotdop to represent global R&D interest in DoP.  
USA Pharmaceutical Sales 
 The global pharmaceutical drug market is opaque and heterogeneous. Drug 
companies often do not report their exact medicine sale figures, and sometimes the 
figures that are reported do not match the reality (Clifford & Creswell, 2009; Simoens, 
2011). Pharmaceutical companies donate medicine or use special formulas to determine 
the cost of medicine in a country, which alters the sales reports. As a result, it is difficult 
to aggregate medicine sales across companies and disease areas (Frank, 2001). 
 Despite the lack of data on global medicine sales, there is accurate data about 
USA drug sales. Bloomberg Finance L.P. collects information on pharmaceutical 
companies, medicine sales, and medicine pipelines. They also aggregate the data to report 
USA pharmaceutical sales across many disease categories. Bloomberg Finance L.P. is 
one of the largest financial data news corporations. It controls about “a third of the 16 
billion global financial data market” (Clifford & Creswell, 2009).  
 Even though I am limited to USA medicine sales, I am able to understand many 
things about the world market from this limited dataset. USA medicine sales are a good 
proxy for originator drug firms’ market. In 2000, the USA was 53% of the world’s 
healthcare market (World Health Organization, 2004); other high-income countries, 
which have a similar disease profile as the USA, made up 36% of global pharmaceutical 




innovative country for pharmaceutical development, so medicine sales and priorities in 
the USA can direct global markets. As one scholar says, “Emerging markets’ emphasis 
on generic medicines coupled with European countries’ price regulations means that U.S. 
consumers continue to provide originator firms with more revenue per person than 
consumers in other countries” (Blume-Kohout, 2012). As a result, I include USA sales in 
the analysis as a proxy for the market size for new and innovative medicines. 
 To find information on disease market size, I search for medicine sales of major 
illnesses in Bloomberg’s drug database. Each disease search produces a list of applicable 
medicines that treat the disease and information such as the active molecule, 
manufacturer, sales volume, and sales in dollars for those medicines. I collected annual 
sales from 2006-present. Out of the 136 diseases in the WHO burden of disease data, 
Bloomberg has financial data for 58 diseases. In the regression analysis I use the variable 
usasales2010 to represent 2010 USA sales.  
Data for Dependent Variables 
Web of Science  
The dependent variables in this study come from three different databases: WoS, 
PubMed, and PatStat. WoS is a prominent scholarly publication database that indexes 
over 14,000 journals in natural sciences, social sciences, and humanities (Thomson 
Reuters, 2012). The database is used in numerous bibliometric studies, and scholars have 
developed tools to analyze scientific trends within WoS (Leydesdorff, Carley, & Rafols, 
2013). The database has become such a central repository for scholarly work that pay 
structures, scientific research incentives, and science policy are based on whether an 




 For this dissertation, I used a WoS nanotechnology database created by Arora et 
al. (2012). From 2000-2012, Arora et al. found 770,000 WoS nanotechnology articles. I 
then used a NM keyword strategy to extract all the NM articles from their database using 
the health keyword strategy in Table 4. There are about 81,800 NM articles from 2000-
2012. 
 Moreover, I searched WoS for articles written or funded by formal PPPs. Details 
about this search are found in the PPP section below. The PPP search was used to 
compare NM research to PPP research. 
PubMed 
PubMed is a journal database that focuses on health and biomedical journals. It is 
run by the USA National Institutes of Health (NIH) (National Institutes of Health, 2013), 
and it indexes 5,600 journals from 1946 until the present. PubMed has several features 
that make it a good a database for this study. First, it is a free and easy to access 
comprehensive database of biomedical and health journals. Several other studies use 
PubMed as a database in their health-related bibliometric studies (Bonaccorsi & Daraio, 
2003; Falagas et al., 2006). In addition, the NIH requires that all NIH-sponsored research 
be available on PubMed (National Institutes of Health, 2014). Since the NIH is the largest 
funder of medical research, PubMed is a major repository for biomedical research.  
 To find nanotechnology articles in PubMed, I used the same keyword search 
strategy created by Arora et al. (2012). I did my search on March 6, 2013, on all available 
fields. From 2000-2012, PubMed had 224,500 nanotechnology articles.  
Once I had the nanotechnology articles from PubMed, I searched for the health 




keyword strategy is found in Table 4). There were 58,360 NM articles from 2000-2012 in 
PubMed. 
PatStat 
 The European Worldwide Patent Statistical Database (PatStat) is an openly 
available database of worldwide patents. It has data from over 100 countries and contains 
about 60 million patent applications (EPO, 2011). PatStat is commonly used by other 
bibliometric studies, and it is one of the standard databases used in patent analyses 
(Hullmann & Meyer, 2003; Maclurcan, 2010b).  
The nanotechnology patent database was created using the same search terms as 
Arora et al. (2012). I then used the health keyword strategy (Table 4) to find the NM 
patents. However, in addition to the keyword search, I searched for NM patents based on 
their International Patent Classification (IPC) code. I extracted articles with the IPC code 
A61. A61 is the patent classification for medical and hygiene patents. Within A61, I 
excluded veterinary patents.  
Unlike the WoS and PubMed databases, PatStat has complete patent data only 
from 2000-2009. As a result, instead of using 2010 data for patents, I analyze 2009 
patents. Using 2009 data does not introduce too much bias into the results because there 
is a high data correlation between the years. For example, the correlation between 2009 
and 2008 patent data is 0.98. PatStat only has 13,000 NM patents, while WoS has 81,812 
and PubMed has 58,630 NM articles. Despite the differences in size, NM still represents 
13% of the nanotechnology patent database. In comparison, NM is 11% of the 
nanotechnology WoS database. Figure 1 shows the number of NM articles in all three 




number of NM publications and patents. In addition, the graph shows that there are 
significantly more publications than patents for each year.  
 
FIGURE 1 NM PUBLICATIONS IN WEB OF SCIENCE, PUBMED, AND PATSTAT 
  
Comparison Group 
 In order to better understand the nature of NM R&D, I compare it to a random set 
of WoS publications from 2009 and 2010. The 2009 articles were given to me directly 
from Thompson Reuters (the owners of WoS), and I generated a random set of 2010 
articles by downloading all the articles that had the randomly generated number 29 in the 
digital object identifier (DOI). There were 40,000 random articles in 2009 and 1,376 in 
2010. 
Methods 
Health Keyword Strategy 
 My search strategy for NM was similar to many other nano/bio bibliometric 
studies (Chen & Guan, 2011; A. Porter, Youtie, Shapira, & Schoeneck, 2007). To create 
the search keywords, I first developed a large list of keywords that could possible 
generate NM articles by reviewing highly cited NM articles (Invernizzi, 2006; Wagner et 




keywords that did not contribute any unique articles. This step ensured that the keywords 
are encompassing and generate “a sizable quantity of articles” (A. Porter, Youtie, 
Shapira, & Schoeneck, 2007). By removing these keywords, I reduced the number of 
keywords in my search strategy from about 150 phrases to 29 phrases while only losing 
5% of the articles.  
 Next, I verified the accuracy of each keyword by testing if it generated relevant 
NM articles. Each keyword had to correctly identify 70% of the articles as NM in order 
for it to stay in the search strategy. In general, 70% keyword accuracy is a benchmark 
used by other bibliometric scholars (as discussed in personal correspondence with Alan 
Porter). For example, two inaccurate keywords were health and surgery. Though these 
keywords appear to be closely related to medical articles, they generate a lot of non-
medical research. Additionally, I edited several keywords so that they would be more 
specific. For example, I edited “dental” so that it excluded articles that contained 
“accidental” but did not have any relationship to health.  
 In each iteration of the search strategy, I asked a NM expert to verify that the 
search generated NM articles. I gave the NM expert a random set of papers from my 
search, and she classified them as NM. She also gave a brief explanation of why the 
paper was or was not NM. Through this process, I further refined and removed words to 
better reflect the actual NM literature. For example, in the first set of nanotechnology 
searches, I included words like toxicology. After talking with the expert and reading 
various definitions of NM, I realized that nanotechnology toxicology studies are not 





 After I developed the keyword strategy, I used it to search the nanotechnology 
databases I previously created in WoS, PatStat, and PubMed. Table 4 contains the final 
list of health keywords that I used in search.  
 
TABLE 4 HEALTH KEYWORD SEARCH TERMS 
alzheimer dental neuron 
anemia disease orthopedic 
antibiotic dopamine pharma 
antitumor drug physiological 
blood HIV skin 
brain insulin therapeutic 
cancer liver tissue 
cholesterol measles vaccine 
clinic medicine wound 
 
Disease Search Strategy 
 Next, I developed a set of keywords to find specific diseases within NM 
publications and patents. I used the WHO BoD study as a list of the world’s major 
illnesses (see Table 2). Then, I looked for alternative names for each disease in WebMD 
to make the search robust.  In general, most diseases had unique names; therefore, they 
were easy find and code in the database. However, it was difficult find keywords to 
classify some illnesses such as obstructed labor or maternal hypertensive disorders. From 
the list of diseases, I built a thesaurus to search the NM database (see Appendix A for the 
list of disease search terms). About 24,500 NM articles, or about 30%, related to a 
specific disease.  The other 70% of articles relate to healthcare, but they cannot be 




PPP Search and Analysis 
 My first set of hypotheses examined the role that formal PPPs play in NM. My 
hypothesis was that formal PPPs are major actors in DoP NM research because other 
studies found that 75% of DoP research was conducted by formal PPPs. However, as 
described in Chapter 4, very few PPPs did research on nanotechnology. As a result, I 
compared PPP and NM research by asking several different types of questions. For 
example: Are they focusing on different diseases? Is the research concentrated in 
different areas of science? To compare PPP and NM research, I first created a list of 
formal health PPPs from Policy Cures and the broader literature on PPPs. Then I 
downloaded all the articles written by formal health PPPs in WoS2. Overall, I searched 
for articles from 28 different formal PPP organizations in WoS. Table 5 lists all of the 
PPPs that I used in this study.  
  
                                                          
2 For this part of the analysis, I did not use PatStat and PubMed. I could not use PatStat because I did not 
have access to the database. I did not use PubMed because many of the analysis tools in this study are 




TABLE 5 LIST OF FORMAL HEALTH PUBLIC-PRIVATE PARTNERSHIPS 
List of formal PPPs 
Aeras International AIDS Vaccine Initiative 
(IAVI) 
BuruliVacConsortium International Partnership for Microbicides 
(IPM) 
Consortium for Parasitic Drug Delivery International Vaccine Institute (IVI) 
Drugs for Neglected Diseases initiative (DNDi) Malaria Vaccine Initiative (MVI) 
European Vaccine Initiative (EVI) Medicines for Malaria Venture (MMV) 
European and Developing Countries Clinical Trials 
Partnership  
Meningitis Vaccine Project (MVP) 
European Solutions Enterprise on Neglected Diseases Novartis Institute for Tropical Diseases 
Foundation for Innovative New Diagnostics (FIND) OneWorld Health (OWH) 
Global Solutions for Infectious Diseases Program for Appropriate Technology in 
Health (PATH)  
Global Alliance for TB Drug Development (TB 
Alliance) 
Sabin Vaccine Institute 
Global Alliance for Vaccines and Immunisation The Vizier Project 
Global HIV Vaccine Enterprise TI Pharma 
Infectious Disease Research Institute (IDRI) TuBerculosis Vaccine Initiative (TBVI) 
Innovative Vector Control Consortium (IVCC) WHO: Special Programme for Research and 
Training in Tropical Diseases (WHO/TDR) 
 
 Once I had the PPP and NM databases, I conducted several analyses to compare 
the two sets of articles. First, I compared NM and PPP articles to determine if they focus 
on different diseases and subject areas, and if they utilize disparate sources of knowledge. 
Second, I mapped each population’s research to determine the relationship between 
scientific fields and sub-disciplines based on factors such as co-authorship and citation 
patterns. These maps were made using the protocol described by Rafols et al. (Rafols, 
Porter, & Leydesdorff, 2010).  
 Then, I calculated the integration and specializations score of the PPP articles and 
NM articles. The integration score describes the breadth of knowledge that is used to 
write an article. If the authors use a variety of articles from very disparate fields to write a 




cite papers from other disciplines, then the paper has a low integration score because it 
only draws knowledge from a narrow set of fields. Integration scores are calculated using 
the citations from each article (A. L. Porter & Rafols, 2009). Equation 2 shows how to 
calculate the integration score. Sif is the cosine similarity matrix between two different 
subject categories and Pi is “the proportion of references citing the subject category i in a 
given paper” (A. L. Porter & Rafols, 2009) 
EQUATION 2 CALCULATING INTEGRATION SCORE 
   
 The specialization score measures the diversity of a group of articles based on 
where they are published. If a scientist publishes articles in journals ranging from 
economics to nuclear physics, then the scientist is not specialized. However if a scientist 
only publishes in journals in one narrow field, then that scientist is very specialized. 
Specialization is another way to describe the interdisciplinarity of a set of papers 
spanning fields, and it shows the potential influence of a set of paper. Interdisciplinarity 
is important because many scholars believe that the most innovative scientific discoveries 
occur at the boundaries of traditional disciplines (Hollingsworth, 2008; Moed et al., 
2005). Equation 3 shows how to calculate the specialization. The equation to calculate 
specialization is very similar to the equation to calculate integration, but instead of using 
the subject categories of the cited journals, specialization uses the proportion of subject 




EQUATION 3 CALCULATE SPECIALIZATION 
 
 The results of the integration and specialization score analysis are found in 
Chapter 4. 
Qualitative Data  
 As I analyzed the quantitative analysis, I simultaneously collected and analyzed 
qualitative data. The qualitative data comes from two main sources; first, I examined the 
websites of the formal PPPs, and second, I conducted semi-structured interviews of PPP 
scientists and managers. Traditionally, a website is one of the main information portals of 
a PPP; as a result, a PPP would put a lot of relevant information on the website that I 
could not obtain during an interview. For example, most of the websites discuss how the 
organization was founded, but many interviewees did not know the history of their 
organization. A weakness of using a PPP website is that it provides a narrow image of the 
organization. PPPs design their websites to portray their organization favorably, so it is 
unlikely that the websites will discuss the failures of the PPPs. Also, the websites will not 
provide information on topics that are not central to the mission of the organization. 
Therefore, subjects such as NM do not appear on most PPP websites.  For each website, I 
downloaded the relevant text and uploaded it to Nvivo (qualitative data management 
software) to be coded and analyzed. I followed standard content analysis procedures in 
order to extract the necessary information (Krippendorf, 1980). For more information on 




The interviews help offset the deficits of the websites and allow me to triangulate 
my information from two types of sources. I selected my interview participants through a 
variety of purposive sampling techniques. First, I identified major PPPs involved in drug 
research for neglected diseases. Policy Cures maintains a comprehensive list of these 
organizations, and I contacted all 28 of them for interviews. I tried to interview 
executives and managers at the various PPPs, but sometimes I spoke with media/public 
outreach officials. I also interviewed scientists that partnered with PPPs. To schedule an 
interview, I sent all the active PPPs emails requesting an interview, and I directly called 
several of them. Appendix B shows a sample of the email contact letter and the letter 
outlining the participants’ rights, and Table 6 shows the response rate of interviews. I 
conducted 14 interviews of managers/scientists of 10 PPPs and 3 universities. My overall 
response rate was 34%, but the response rate of the PPPs was slightly higher at 41%. I 
interviewed 10 out of the 24 current PPPs. Four of the 28 PPPs are either defunct or they 
merged with another organization. The few PPPs that declined the interview stated that 
their organizations did not conduct research, and as a result, they did not feel their 
opinion would be useful for the dissertation.  









41 14 10 34% 
 
There are some non-response biases associated with this study because the 
individuals who participated in the interviews have different characteristics from the 
participants who did not respond to the interview requests. One source of non-response 




people at American PPPs and five people at European PPPs. Although the study would 
be stronger if I interviewed an Asian-based PPP, there are only two Asian PPPs, and 
therefore, the non-response is not severe. Another non-response bias is that none of the 
PPP founders agreed to an interview. The PPP founders could have a different 
perspective on PPPs compared to scientists and senior executives, and as a consequence, 
there is a potential for biased results.  
I checked for other possible non-response biases, and there is no evidence that the 
study suffers from any others. I interviewed PPPs that focused on a variety of diseases 
such as TB, Malaria, HIV/AIDS, buruli, and leishmaniasis, and I interviewed managers at 
both large, globally renowned PPPs and smaller PPPs. I also interviewed both scientists 
and communications specialists, which allowed me to get opinions across job 
descriptions. Finally, I interviews scientists and managers who work at old and new 
PPPs.  
I conducted 30-minute to 1-hour semi-structured interviews. Table 8 gives a list 
of the interview questions. I recorded and transcribed all the interviews and uploaded 
them into Nvivo for analysis. Table 7 shows the coding scheme used on the qualitative 
data. The initial codes were developed based on the major themes of the dissertation, and 
they covered a variety of topics such as the research funding and R&D portfolios of the 
PPPs. As new themes arose in the qualitative data, more codes were added to the project. 
The recording units for the analysis are sentences and paragraphs because it allows the 




Table 7 Codes for qualitative data 
Codes Code Explanation 
Disease of poverty Any mention of a disease of poverty 
Diseases Any mention to a non-DoP 
Drug Delivery Any mention to drug delivery systems 
Funding information on who funds the PPP or how much money they have 
Future any reference to the future ( i.e. the future of the PPP or DoP research) 
Governance Information on the governance structure of the PPP 
History History/origins of the PPP start?  
International Any mention to countries working with PPP 
Model Explanation of the PPP model and why it is important 
Nanotechnology  Any reference to nanotechnology 
Partners Who is the PPP working with? 
Portfolio Information on the research projects 
Publishing/patenting Information on publishing and patenting habits of organization or 
researcher. 
Scientist Any reference to a specific researcher 
Sensors Any reference to sensor technology 
Skills Mentioning a specific skill of scientists or the PPP 
 




Table 8 Interview questions 
Interview Questions 
Introduction/ What is your background? 
Background What do you do within your organization? 
  Give a brief overview of your organization? 
Research/ Focus What is your research? 
  Who funds your research? 
  How did you choose your research area? 
  What are some successes you have had in your research? 
  Who are your research partners? 
  How long have you been working in this area? 
  What types of project will you do in the future? 
Nanomedicine Are you doing any work in NM? 
  Why (or why not) are you doing work in NM? 
  Do you think NM is useful for DoP? 
PPP Do you consider your organization a public private 
partnership? If so why? 
  What is the structure of your PPP? 
  Who funds the PPP? 
  Where do PPPs fit within research and drug discovery? 
  Are PPPs necessary to find medicines for diseases of poverty? 
  How does your organization use patents, and publications? 
  How does your PPP choose its research foci? 
  Do you think PPPs are the new normal for drug development 
  Do you collaborate/talk with other PPPs? 
  All PPPs seemed to spring up at the same time. Do you have 
any clues why? 
DoP In your opinion what are the most problematic diseases of 
poverty? 
  What research areas are necessary to reduce the burden of 







As mentioned before, I used several different types of software to analyze the 
data. To sort, clean and search the bibliometric data, I primarily used VantagePoint, 
which is a text mining software that specializes in organizing and analyzing text based 
data. Within VantagePoint, created search thesauri, filtered the R&D to relevant topics, 
and cleaned the data so that I could verify that authoring institutions. I also used several 
macros to calculate the integration and specialization scores of the various datasets. After 
cleaning and sorting the data in VantagePoint, I exported the data to Microsoft Excel and 
Stata for further analysis. 
 For the analysis, I did a 2010 cross sectional analysis of NM.  I chose 2010 
because nanotechnology had at least 10 years to develop as a field. Scholars had time to 
fund, complete and publish their research results in WoS indexed journals. As a result, I 
can better assess NM as a field. In addition there is accurate 2010 BoD and USA 
medicine sales data. The fidelity of the data gives the analysis more power.  
Regression Techniques 
 The dependent variables in this analysis, the number of publications and patents 
per disease area, are count data that have Poisson distributions. Therefore, I use Poisson 
regression techniques as opposed to ordinary least squares regression to analyze the data 
(Coxe et al., 2009). Figure 2 shows the distribution of the WoS 2010 NM data. Most of 
the disease areas are associated with very few articles and therefore the density of articles 
is close to 0 publication. However, there are a few diseases, such as breast cancer, that 






FIGURE 2 DISTRIBUTION OF 2010 WEB OF SCIENCE NM DATA 
  
 The Poisson distribution is given by Equation 4. It “gives the probability of 
observing a given value, y, of variable Y” where µ is the mean of the number of 
publications/patents (Coxe et al., 2009). The typical regression model takes the form of 
Equation 5. 
EQUATION 4 POISSON MASS DISTRIBUTION FUNCTION 
 
 
EQUATION 5 TYPICAL REGRESSION MODEL WITH POISSON DISTRIBUTION 
 
One major assumption in Poisson models is that the mean and variance of the 
dependent variables are equal. If they are not equal, as in this case, scholars recommend 
using negative binomial regression models (Coxe et al., 2009). Table 9shows the mean 
and variance for the various dependent variables in this study.  
Another assumption with Poisson analyses is that the dependent variables do not 



































































of patents made by a scientist, the analysis could suffer from excess zeroes because some 
scientists never patent a technology. Therefore in this type of analysis, I first have to find 
the probability of a scientist patenting research (a logistic regression) and then I can use 
the Poisson analysis to test the probability that a scientist has more than 0 patents. This 
type of regression is called a zero inflated negative binomial regression. For this analysis, 
I find that the data is not zero inflated so I do not have to run a zero inflated negative 
binomial regression.  
TABLE 9 MEAN AND VARIANCE FOR THE DEPENDENT VARIABLES 
  Mean Variance 
WoS 2010 22.79 296,998.00 
PubMed 17.18 1,351.48 
PPP 6.28 309.68 
PatStat 1.42 17.50 
Comp09 55.36 7,519.69 
Comp10 3.58 59.41 
 
An example of the regression equation I use in this analysis is given by the following 
equation: 
ln(wos2010) = b0 + b1*usasales2010 + b2*bod2010 + b3*increase + b4*dop + e 
Limitations 
 Even though bibliometric analyses have become standard practice, this research 
method has limitations. First, journal databases such as WoS and PubMed tend to have 
more journals in English and from rich countries. This means that I am are more likely to 
bias the analysis in favor of English speaking, western countries (UNESCO, 2005). Also 




so research on these diseases may not be published in broad, globally focused journals 
that are indexed in WoS and PubMed.  
 In addition to the limitations of the patent and publication datasets, the burden of 
disease statistics has limitations. As discussed before, it is difficult to collect accurate 
disease burden statistics for very poor countries, which means that the disease burden 
statistics for developing countries may not be as accurate as the data for rich countries 
(Murray et al., 2012). Also the burden of disease in developing countries could be 
underestimated because individuals in poor nations do not see doctors at the same rate as 
rich countries. In a poor country, people may only see the doctor in the most severe life 
threatening cases and therefore, chronic illnesses such as back pain, and Alzheimer’s 
would be left undiagnosed and not counted in the national disease burden statistics 
(Murray et al., 2012). 
 There are also limitations with USA medicine sales data. The medicine market is 
very opaque and it is hard to track global sales. Companies often do not report drug sales 
for specific medicines and there are a variety of pricing structures that vary between 
countries (Frank, 2001; Simoens, 2011). For example, pharmaceutical company may 
donate the medicine or negotiate special pricing structures for poor nations. The data 
limits the conclusions I can draw from the results.  Another issue with USA medicine 
sales is that it covers a limited number of diseases. The database used to track medicine 
sales, Bloomberg Financial L.P., does not track medicine sales for many diseases such as 
neonatal infections and so my regression analysis with USA medicines sales have fewer 
observations. The lack of data limits my ability to run regression analyses with that 




The second part of the analysis consisted of qualitative data analysis of websites 
and interviews. I collected website data from 28 different PPP, but I was only able to 
conduct 14 different phone interviews spanning 10 different PPPs. Like many methods, 
there is a potential non-response bias. The answers of those that were interviewed may be 
different than the individuals that chose not to be interviewed. Fortunately, from 
examining websites, I could triangulate the correct information from a variety of sources.  
Conclusion 
 This chapter summarizes the data and methods that I use for this dissertation. The 
data sources can be divided into two broad types of data. First I use quantitative data to 
analyze publication patterns of NM research. I use data from Bloomberg L.P., the WHO, 
G-FINDER, WoS, PubMed, and PatStat.  Then I use negative binomial Poisson 
regression analyses to determine the relationship of the USA medicine sales, disease 
burden and PPP R&D investment with NM publications and patents. 
 The qualitative data was from formal PPP websites and interviews. I conducted 
14 semi-structured interviews of different scientists and PPP managers and I analyzed 28 
different PPP websites. From this data, I can better understand the purpose of PPPs and 





CHAPTER 4: QUANTITATIVE ANALYSIS RESULTS 
 
Introduction 
 This chapter summarizes the findings from the quantitative analysis. The chapter 
begins by summarizing the main research questions and hypotheses. Then, I discuss the 
descriptive statistics and correlation matrix of the different variables and review the 
results from the negative binomial regression.  Finally, I discuss the finding from the 
comparison between PPP and NM research.    
Research Questions 
I have several research questions and hypotheses that I am testing for this 
dissertation. First, I am investigating how USA medicine sales, disease burden and DoP 
relate to the number of NM publications and patents. The questions and hypotheses are 
below: 
Q1.1: Do diseases with high USA medicine sales have more NM R&D than 
diseases with low medicine sales?  
H1:1 High USA medicine sales for a disease are associated with more NM 
publications and patents for that disease. 
Q1.2: Does disease burden for a specific disease correlate with the amount of NM 
research and development for that disease? Do diseases with growing disease 
burden receive more research attention? 





H1.2b: Diseases that have increasing disease burden have more publications and 
patents. 
Q1.3: Is there less NM research for DoP than other diseases?  
H1.3a: There are fewer NM publications and patents on DoP compared to other 
diseases, controlling for medicine sales and disease burden. 
H1.3b: DoP with more PPP funding (hotdop) have more NM publications and 
patents than other DoP with less PPP funding. 
My second research question examines how public private partnerships affect 
research on disease of poverty in NM. The literature suggests that pharmaceutical 
companies neglect DoP because the companies cannot recoup their R&D expenses from 
selling medicines for DoP. As a result, medicines are not developed for many diseases 
that have large disease burdens (Kremer, 2002).  
 Many scientists propose that public private partnerships (PPPs) could fix this gap 
because these organizations have different motivations and incentives than 
pharmaceutical companies. PPPs bring together government, private, and non-profits in 
order to tackle a specific problem. Over the past few decades, PPPs rose in prominence, 
and more recently, health PPPs and product development partnerships (PDPs) have 
become more important in this area.  
 Given the importance of PPP in DoP medical research, I assumed that PPPs 
would play a prominent role in NM PPP research. My original hypothesis was: 
H2.1: NM DoP research is more likely to be conducted by formalized PPPs than 
other organizations, controlling for variables such as drug sales, disease burden 




However, this hypothesis is not supported by the data. There are very few PPPs 
publishing or patenting NM research even though there is significant research on DoP 
with NM. In WoS less than 100 out of 81,200 articles were funded or authored by 
scientists at PPPs. But, if PPPs are not doing DoP NM research, then who is conducting 
this research? What organizations and research labs are studying NM for DoP? 
Moreover, what type of research are formal PPPs doing and is it different than NM 
researchers? Are they working in the same field? Are they drawing upon the same 
sources of knowledge (integration)? Are they publishing in the same journals 
(specialization)? I analyzed PPP and NM research articles from WoS in order to 
understand the similarities and differences between these two populations. 
H2.2: PPPs’ publications focus on different diseases than NM publications.  
H2.3: PPPs’ publications focus on different fields and sub disciplines than NM 
publications.  
H2.4: PPPs partner with different organizations than NM researchers.  
H2.5: PPP publications have lower integration scores than NM publications.  
H2.6: PPP publications have higher specialization scores than NM publications. 
Descriptive Statistics 
For this analysis, there are six dependent variables. The first three dependent 
variables are the number of 2010 NM publications in WoS (wos2010), the number of 
2010 NM publications in PubMed (pubmed2010) and the number of 2009 NM patents in 
PatStat (patstat2009)3. The fourth dependent variable is the number of 2010 articles 
                                                          





written or funded by PPPs in WoS (ppp2010). Finally, the last two dependent variables 
are the number of medical articles in the 2009 and 2010 comparison groups (comp09 and 
comp10). 
There are five independent variables for this study: bod2010, increase, 
usasales2010, dop, and hotdop. Table 10 lists all the variables and Chapter 3 gives more 
details about each of the variables.  
TABLE 10 LIST OF VARIABLES 
wos2010 Number of NM publications in Web of Science in 2010  
pubmed2010 Number of NM publications in PubMed in 2010 
patstat2009 Number of NM patents in PatStat in 2009 
ppp2010 
Number of research articles in Web of Science by public private partnerships 
in 2010 
comp09 Number of medical articles in 2009 comparison group 
comp10 Number of medical articles in 2010 comparison group 
bod2010 2010 disability adjusted life years of disease x (in millions of DALY) 
increase Difference in DALY between 2010 and 2005 
usasales2010 USA medicine sales for a particular disease in 2010 (in $million) 
dop  Is the research about a disease of poverty? 0=no, 1=yes 
hotdop Amount of Funding from PPPs in 2010 (in $million) 
 
Table 11 shows the descriptive statistics of the variables and it reports the number 
of observations, the mean, standard deviation and range of the variables. Each 
observation represents a different disease. The third column reports the mean number of 
publications and patents per disease area. On average there are more disease-specific 
WoS NM articles (22.79) than PubMed articles (17.18). PatStat has the fewest disease-
specific articles per disease area with an average of only 1.42. The range articles/patents 
for each dependent variable is also varied. WoS has a large range, 0 to 443, while the 




Another interesting observation about that data is that the WoS and PubMed 
databases have more nanotechnology publications associated with the a disease than 
PatStat; 4.5% of nanotechnology articles in WoS and 9.6% of nanotechnology articles in 
PubMed publications are disease specific while only 1.2% of NM patents are disease 
specific (see Table 12).  This is unexpected considering that patents are more closely 
associated with an end product while publications are more associated with basic 
research.  
The patent database is much smaller than the WoS and PubMed databases. In 
2010 there were 91,000 nanotechnology articles in WoS and only 23,000 nanotechnology 
patents. Despite the differences in size, about the same proportion of articles or patents 





TABLE 11 SUMMARY STATISTICS OF DEPENDENT AND INDEPENDENT VARIABLES 







Number of NM publications in PubMed in 
2010 (pubmed2010) 
130 17.18 36.76 0 249 
Number of NM publications in Web of 
Science in 2010 (wos2010) 
130 22.79 54.50 0 443 
Number of NM patents in PatStat in 2009 
(patstat2009) 
130 1.42 4.18 0 42 
Number of articles in Web of Science by 
public private partnerships in 2010 (ppp2010) 
130 6.37 17.56 0 127 
 
Independent Variables # Observation Mean Std. 
Dev. 
Min Max 
2010 disability adjusted life years of 
disease x (in millions of DALY) 
(bod2010) 
98 63.17 93.46 0.02 519 
Difference in DALY between 2010 
and 2005 (increase) 
98 -2.09 13.38 -75 27 
USA medicine sales for a particular 




4764.64 0.06 19,525 
Is the research about a disease of 
poverty? 0=no, 1=yes (dop) 
130 0.23 0.42 0 1 
Amount of Funding from PPPs in 2010 
(in $million) (hotdop) 
30 93 234 0 1,070 
  
The independent variable 2010 burden of disease (bod2010) has a large range (see 
Table 11). The illness with the highest disease burden in the world is ischemic heart 
disease. It caused 519 million DALYs in 2010 and it is growing in severity (Murray et 
al., 2012). The average burden of disease in 2010 is 63.17 million DALYs. This is lower 
than the 2005 burden of disease by 2.09 million DALYs. This means that the average 
severity of the diseases in the dataset decreased from 2005 until 2010.  
 Another independent variable, USAsales2010, also has a large range. That data 
was collected from Bloomberg Finance L.P. and it represents the 2010 USA medicine 




unipolar depression disorders with $19.5 billion and the average 2010 USA medicine for 
a particular disease in the dataset sales is $3.5 billion. However, as stated before, there 
are only sales data for 63 disease areas. Finally, the last variable, hotdop, tracks the 
amount of PPP funding for DoP in 2010. This data comes from Policy Cure’s G-FINDER 
database and it only measures funding for DoP. Each of the 30 DoP received an average 
of $93 million worth of funding from PPPs. 
 Table 12 compares WoS nanotechnology articles to the comparison groups.  The 
comparison groups have higher percentages of health articles, disease specific articles 
and DoP related R&D than the nanotechnology database. For example in 2009, 33.1% of 
the articles in the comparison group are related to health while only 12.7% of the 
nanotechnology articles in WoS are related to health.  Moreover in 2009, 2.1% of articles 
in the comparison group relate to DoP while only 0.3% of WoS nanotechnology articles 
relate to DoP. I was not able to run a statistical test on these results, but it appears that 
nanotechnology is less focused on medical issues and DoP than overall scientific 
research.   





0 patstat2009 ppp2010 Comp09 
Comp1
0 
total publications 91,301 29,853 22,837 734 40,000 1,376 
total health 11,625 7,998 2,645 614 13,247 677 
total disease 4,099 2,853 285 540 6,546 418 
total DoP 301 248 14 452 850 28 
% health 12.7% 26.8% 11.6% 83.7% 33.1% 49.2% 
% disease 
specific  4.5% 9.6% 1.2% 73.6% 16.4% 30.4% 





Table 13 is an illustrative list of diseases and some of their statistics. This chart 
gives a small snapshot of the dataset. For example, ischemic heart has a very high disease 
burden, but it does not have as many publications as cancer and periodontal disease. The 
research gap is even more apparent when comparing breast cancer and meningitis. The 
disease burden for both these diseases is about 50 million DALYs, but breast cancer has 
50 times more publications than meningitis.  
 


































519.28 82 44 0 6117.28 12.27   
Malaria 330.74 39 38 0 194.54 -74.75 x 
HIV/AIDS 326.19 93 99 5 6753.76 -59.14 x 
tuberculosi
s 
197.58 51 33 3 0.06 4.32 x 
Asthma 89.84 32 21 2 15165.83 2.93   
Diarrheal 
diseases 
87.66 48 27 2 233.09 -13.46 x 
Meningitis 52.75 8 4 0 78.06 -0.55 x 
Breast 
cancer 




45.40 150 118 9 5462.21 7.09   
Periodontal 
disease 
21.64 212 153 42 564.78 2.19   
Tetanus 18.65 8 3 0 1219.76 -9.33 x 
Prostate 
cancer 
15.15 160 80 4 2120.74 1.69   
 
Table 14 shows the correlation matrices of the dependent and independent 
variables. In this table there is a high correlation (0.96) between WoS (wos2010) and 




PubMed have similar information. WoS and PubMed should have similar patterns 
because there is a large overlap between the biomedical journals in PubMed and WoS 
(Falagas et al., 2006).  
TABLE 14 CORRELATION MATRIX OF VARIABLES 
 Wos2010 Pubmed2010 patstat09 Ppp2010 comp09 comp10 daly10 dop usasales2010 increase hotdop 
Wos2010 1.00           
Pubmed2010 0.96 1.00          
patstat09 0.58 0.64 1.00         
ppp2010 0.10 0.13 0.04 1.00        
comp09 0.79 0.78 0.34 0.16 1.00       
comp10 0.88 0.84 0.61 0.02 0.84 1.00      
daly10 0.07 0.10 -0.02 0.39 0.31 0.14 1.00     
dop -0.12 -0.14 -0.13 0.37 -0.19 -0.19 -0.07 1.00    
usasales2010 0.16 0.11 -0.07 -0.11 0.36 0.21 0.18 -0.20 1.00   
increase 0.03 0.00 0.04 -0.69 0.05 0.13 -0.26 -0.25 0.19 1.00  
hotdop 0.12 0.18 0.05 0.81 0.17 0.02 0.40 0.33 -0.02 -0.67 1.00 
  
Another important observation from Table 14 is that there is a lower correlation between 
patent and publication databases. The correlation between PatStat (patstat09) and WoS 
(wos2010) publications is only 0.58 and the correlation between PatStat and PubMed is 
0.64. The lower correlations between the databases is not surprising since publication and 
patents measure different aspects of the R&D process. In general, publications are 
associated with basic research while patents represent R&D that has a market potential 
(Moed et al., 2005). Finally, there is very little correlation between articles published by 
PPPs in 2010 (ppp2010) and the other datasets. This is expected since the articles 
published by PPPs in WoS focus almost exclusively on DoP.  
Table 14 also shows the correlations for the independent variables. Overall, the 
independent variables are not highly correlated. The variables with the highest correlation 




shows that a high burden of disease is associated with more PPP funding.  Another set of 
variables that are highly correlated are 2010 PPP funding (hotdop) and the difference in 
disease burden from 2005 until 2010 (increase). These variables have a large negative 
correlation (-0.88) which means that PPPs tended to fund research on diseases with 
decreasing disease burden. Finally, the large positive correlation (0.8) between 2010 USA 
medicine sales (usasales2010) and 2010 PPP funding (hotdop) shows that PPPs tend to 
fund research on disease areas that have high USA medicine sales.  
Question 1: Regression Model 
Figure 3 summarizes the research questions. The first research question 
investigates the relationship between USA medicine sales and R&D for NM. USA 
medicine sales are a good proxy for near-term market for originator firms. Originator 
firms are primarily responsible for developing new, patented protected medicines 
(Blume-Kohout, 2012). By examining USA sales I can determine whether the market for 
originator firms has any impact on NM R&D. Hypothesis 1 tests if higher medicine sales 
in the USA (usasales2010) are associated with more NM publications (wos2010) and 






FIGURE 3 REGRESSION MODEL 
The next two hypotheses test the relationship between burden of disease and NM 
R&D. I hypothesize that diseases with higher burden of disease (bod2010) have more 
NM publications (wos2010 and pubmed2010) and patents (patstat2009) and that diseases 
that had increasing disease burden from 2005 until 2010 (increase) have more NM 
publications and patents. The relationship between the increasing disease burden and 
publications/ patents is less clear because there are not studies that examine the change in 
disease burden with patents and publications.   
Finally, I tested if there is more R&D for DoP than non-DoP. I included a dummy 
variable, dop, in the model that tests whether there is more DoP NM R&D than non-DoP 
NM R&D.  
I ran five negative binomial Poisson regressions models on each of the three 
dependent variables.  I started the analysis by simply comparing the dependent variables 
with disease burden (bod2010) and the dummy variable for DoP (dop).     
Model 1: ln(Y) = b0 + b1*bod2010 + e 
Model 2: ln(Y) = b0 + b1*dop + e 




I then ran regression models with USA medicine sales (usasales2010) and the amount 
disease burden increases (increase). 
Model 4: ln(Y) = b0 + b1*bod2010 + b2*dop + b3*increase + e 
Model 5: ln(Y) = b0 + b1*bod2010 + b2*dop + b3*increase + b4*usasales2010 
+ e 
After I ran the regression on NM patents and publications, I repeated the analysis 
with public private partnerships publications (ppp2010) and comparison group 
publications (comp09 and comp10). I am testing whether PPP publications and the 
comparison groups have the same relationship with 2010 USA medicine sales and burden 






Table 15 gives the results of the Poisson regression analysis of NM publication 
and patents. All the coefficients in the table have been transformed, so that they represent 
a multiplicative effect of a 1-unit change in the independent variable. For example, a DoP 
is predicted to have 0.41 times the number of WoS NM articles than a non-DoP.  
From Model 1, I find that disease burden (dop2010) is not related to research 
output. The variable dop2010 is only significant for PPP R&D and the 2009 comparison 
group and in those models the multiplicative effect of disease burden is almost 1. Models 
2 and 3, on the other hand, have very different results than Model 1. In Models 2 and 3, I 
find that DoP have fewer publications that non-DoP and when I control for disease 
burden (dop2010), the effect becomes stronger. For example, among NM WoS articles, 
DoP have about 0.41 times the number of publications compared to non-DoP.  The 
results hold across most of the dependent variable. However; there is one exception; PPP 
articles are 6.68 times more likely to be about DoP than non-DoP.  This is expected since 
most of the PPP were created to focus DoP.   
In Model 4, I examine the impact of the variable increase. Increase represents the 
difference in disease burden between 2005 and 2010. In general the change in disease 
burden has very little impact on R&D and the variable is insignificant for most of the 
regression equations.   
Finally, in the last regression model I test the relationship of USA medicine sales 
(usasales2010) with R&D.  In these regressions, USA medicine sales have a 
multiplicative impact close to one and the variable is insignificant in all the regressions.    




NM R&D.  One reason that the results could be inconclusive is that there is not enough 
USA medicine sales data to test the model. In Model 5 there are only 55 observations 






Table 15 Negative binomial regression results 
  Model 1 Model 2 Model 3 Model 4 Model 5 
WoS coef. z sig coef. z sig coef. z sig coef. z sig coef. z sig 
bod2010 1.00 0.70      1.00 1.56   1.00 0.96  1.00 -0.13   
DoP      0.41 -2.10 * 0.28 -2.77 ** 0.24 -2.71 ** 0.61 -0.51   
Increase              0.99 -0.52  0.99 -0.40   
usasales2010                 1.00 0.98   
constant 26.61 14.57 *** 26.39 16.07 *** 28.27 14.69 *** 30.33 12.95 *** 42.71 12.86 *** 
n= 98    130   98    98   55    
PubMed                               
bod2010 1.00 0.88      1.01 2.31 * 1.00 1.13  1.00 0.15   
DoP      0.38 -2.09 * 0.18 -3.52 *** 0.13 -3.66 *** 0.44 -0.90   
Increase              0.98 -1.03  0.99 -0.77   
usasales2010                 1.00 0.50   
constant 19.22 12.31 *** 20.00 13.67 *** 19.51 12.82 *** 22.86 11.23 *** 33.90 12.30 *** 
n= 98.00     130.00     98.00     98.00     55.00     
PatStat                      
bod2010 1.00 -0.35      1.00 0.79   1.00 0.00  1.00 -0.72   
DoP      0.23 -2.79 ** 0.19 -2.80 ** 0.14 -2.92 ** 0.26 -1.08   
Increase              0.98 -0.93  0.97 -0.99   
usasales2010                 1.00 -0.91   
constant 1.91 2.44 * 1.73 2.48 * 1.98 2.67 ** 2.28 2.77 ** 3.92 3.82 *** 
n= 98     130     98     98     55     
PPP                      
bod2010 1.01 3.37 **    1.01 3.14 ** 1.00 1.61  1.00 1.76 . 
DoP      6.68 4.24 *** 7.32 5.03 *** 5.65 4.34 *** 7.59 3.76 *** 
Increase              0.96 -2.10 * 0.97 -2.13 * 
usasales2010                 1.00 0.08   
constant 3.18 4.59 *** 2.72 4.54 *** 1.37 1.30   1.54 1.71 . 1.62 1.74 . 






Table 15 cont. 
comp09                               
bod2010 1.00 2.06 *    1.006 2.91 ** 1.0054 2.37 * 1.0018 1.16   
DoP      0.40 -2.59 0.01 0.263 -3.86 *** 0.2536 -3.48 ** 0.8858 -0.19   
Increase              0.9974 -0.18  1.0035 0.27   
usasales2010                 1 1.77   
constant 50.80 20.65 *** 64.33 24.29 *** 55.80 21.43 *** 56.75 19.29 *** 71.47 19.26 . 
n= 98.00     130.00     98.00     98.00     55.00     
Comp10                      
bod2010 1.00 1.19      1.00 1.84 . 1.0042 1.63  1.0011 0.55   
DoP      0.21 -3.61 *** 0.17 -3.98 *** 0.1726 -3.29 ** 0.5836 -0.63   
Increase              1.0025 0.15  1.0093 0.54   
usasales2010                 1 1.01   
constant 3.75 5.75 *** 4.39 7.63 *** 4.30 6.50 *** 4.23 5.78 *** 5.9616 6.49 *** 
n= 98.00     130.00     98.00     98.00     55.00     
Significance level: <0.1=. , <0.05=*,<0.01=**,<0.001=*** 
 
After running the regression on the full model, I did a smaller regression with just  
DoP. In this regression, I test if high-profile DoP (such as malaria and tuberculosis) 
receive more research than low-profile DoP. I cannot regress the variable hotdop on the 
full dataset because there is only hotdop data for DoP4.  
For diseases of poverty: 
ln(Y) = b0 + b1*hotdop + e  
The analysis shows that high-profile DoP have slightly more NM publications and 
patents. For every $1 million increase in DoP funding from PPPs, the number of NM 
publications in WoS increases by 1.004 times. This is a very small increase in research 
output. These results hold across all the different databases.  
  
                                                          
4 I also ran this regression analysis including variables like bod2010, usasales2010, and 




TABLE 16 REGRESSION MODEL WITH "HOTDOP" 
WoS Coef z sig 
hotdop 1.004 2.49 * 
constant 3.796 3.89 *** 
      
PubMed Coef z sig 
hotdop 1.007 2.29 * 
constant 1.190 0.36   
      
PatStat Coef z sig 
hotdop 1.004 2.5 * 
constant 0.122 -0.346 ** 
      
PPP Coef z sig 
hotdop 1.005 2.6 ** 
constant 6.130 5.87 *** 
      
comp09 Coef z sig 
hotdop 1.004 2.61 ** 
constant 8.760 6.83 *** 
      
comp10 Coef z sig 
hotdop 1.003 2.01 * 
constant 0.3867 -2.15 * 
n=30    
 
Question 2: PPP and NM comparison 
 Over the past 10 years, there has been exponential growth in the number of NM 
and PPP articles. In 2000 there were only 16 PPP and 1,217 NM articles in WoS, but by 
2010 there were 744 PPP and 11,625 NM articles.  
Table 17 summarizes statistics about PPP research.  The most notable statistic from the 
table is that about 59% of PPP research deals with DoP while only 0.2% of 





TABLE 17 PPP AND NANOTECHNOLOGY RESEARCH OVERVIEW 
  PPP 2000-2012 
Nanotechnology 
2000-2012 
total publications 4,166 769,761 
total health 3,537 81,812 
total disease 3,076 41,368 
total DoP 2,457 1,694 
% health 84.9% 10.6% 
% disease specific 73.8% 5.4% 
% DoP R&D 59.0% 0.2% 
 
 Figure 4 and Figure 5 show the subject categories of NM articles and formal PPPs 
articles. NM involves the fields of nanotechnology and biomedicine and as a result it has 
a lot of subject categories in materials science and biomedicine. PPP articles, on the other 
hand, are more specialized in biomedicine.  
 











Table 18 lists the top subject categories of NM and PPP articles. I restricted this 
table to only list biomedical subject categories (the subject categories that are circled and 
colored red) so that it would be easier to compare the two sets of articles. NM articles 
have a lot of subject categories related to oncology, dentistry and biophysics while PPP 
articles relate more with tropical diseases, immunology and infectious diseases. This 
shows that NM and public-private partnerships conduct research distinctive areas within 
the biomedical field. I also conducted a difference of means test between PPP and NM 
subject categories. The test confirms that there is a statistical difference between PPP and 





TABLE 18 TOP BIOMEDICAL SUBJECT CATEGORIES OF PPPS AND NM 
  Subject Category PPP   Subject Category NM 
1 IMMUNOLOGY 967   PHARMACOLOGY & PHARMACY 10968 
2 INFECTIOUS DISEASES 792  BIOCHEM. & MOLEC. BIOLOGY 7770 
3 PHARMACOL. & PHARM. 551  BIOTECH. & APPLIED MICROBIO 4102 
4 MICROBIOLOGY 521  BIOPHYSICS 3495 




PUBLIC, ENVIR. & 
OCCUPATNL HLTH 437  ENGINEERING, BIOMEDICAL 3110 
7 VIROLOGY 371  CELL BIOLOGY 2452 
8 
Science & Tech - Other 
Topics 344  ONCOLOGY 1911 
9 
Research & Experimental 
Medicine 336  
BIOCHEMICAL RESEARCH 
METHODS 1857 
10 PARASITOLOGY 329  
RADIOLGY, NUC. MEDICN., MED. 
IMAGING 1571 
11 
BIOCHEM. & MOLEC. 
BIOLOGY 294  Research & Experimental Medicine 1347 
12 General & Internal Medicine 197  TOXICOLOGY 1101 
13 Chemistry 178  CHEMISTRY, MEDICINAL 880 
14 RESPIRATORY SYSTEM 137  
DENTISTRY, ORAL SURGERY & 
MEDICINE 839 
15 
BIOTECH. & APPLIED 
MICROBIO 129  IMMUNOLOGY 721 
16 CELL BIOLOGY 79  




GYNECOLOGY 61  GENETICS & HEREDITY 636 
18 PEDIATRICS 61  SURGERY 626 
19 Neurosciences & Neurology 53  NEUROSCIENCES 604 
20 GENETICS & HEREDITY 50   FOOD SCIENCE & TECHNOLOGY 603 
 
Table 19 gives further evidence that PPP and NM scientists study different areas 
by showing the diseases that the scientists are investigating. The top diseases in NM 
articles are breast cancer, neuropsychiatric disorders and periodontal diseases. PPP 
articles, on the other hand, focus on malaria, tuberculosis and HIV/AIDS and other DoP. 
The only disease that is heavily researched by both NM and PPP scientists is HIV/AIDS.  




there is a significant difference in NM and PPP disease topics (See Table 20 for more 
details).  
TABLE 19 TOP DISEASES FOR PPP AND NM ARTICLES 
  PPP 
# 
Articles   NM 
# 
Articles 
1 Malaria 715  Breast cancer 2636 
2 Tuberculosis 537  periodontal disease 1549 
3 HIV/AIDS 421  Oral diseases 1430 
4 Diarrheal diseases 361  skin diseases 1198 
5 Dengue 179  Alzheimer/ dementias 1122 
6 cholera 152   Prostate cancer 961 
7 Respiratory infection 146  Cardiovascular diseases 957 
8 Pneumonia 142  Trachea/bronchus/lung cancers 835 
9 rotavirus 142  Leukemia 763 
10 Leishmaniasis 132   Melanoma/ skin cancers 729 
11 Salmonella Infection 111  Ischemic heart disease 520 
12 Meningitis 97  HIV/AIDS 508 
13 STDs excluding HIV 95  Colon/rectum cancer 482 
14 typhoid fever 86  Ovary cancer 481 
15 
Intestinal Nematode 
infections 82   Parkinson disease 428 
 
 Next I analyzed the integration and specialization scores of NM and PPP articles. 
This analysis was primarily exploratory. If PPP and NM articles have different 
integration and specialization scores, then the populations use and disseminate 
knowledge differently. The integration score measures the range of knowledge that is 
used to write an article. If the article cites papers from a diverse set of fields, the article 
will have a higher integration score than if it only cites articles from one field. The 
integration score for PPP and NM articles are both higher than the average field. Porter 
and Rafols calculated the integration scores from six disciplines and the integration 
scores ranged from the 0.20 in math to 0.65 in medicine research (A. L. Porter & Rafols, 
2009). In this data, the average integration score for NM and PPP articles is about 0.78, 




PPP publications are very similar and there is no statistical difference between the scores 
(see Table 20). This shows that PPP and NM are both integrating knowledge from other 
fields more than other science disciplines although there is not a significant difference 
between PPP and NM research.  
 Specialization measures the extent that a group of papers is narrowly focused in 
one field. For this study I examined the specialization of NM and PPP articles in the 
different disease areas. The mean specialization for NM articles is 0.272, while the 
specialization for PPP articles is 0.351. The difference between these specialization 
scores is statistical significant. In general, PPP research has a higher specialization than 
NM research. This means that PPP researchers are publishing articles in fewer areas than 
NM researchers.  
 Moreover, the average specialization for science in general is 0.67 (A. L. Porter, 
Roessner, & Heberger, 2008). This specialization is significantly higher than the 
specializations for NM and PPP articles. Therefore, even though PPP researchers tend to 
be more specialized than NM researchers, both types of researchers publish more broadly 
than scientists as a whole.  
Table 20 summarizes the disease, subject category, integration score and 
specialization score results. For this analysis, I conducted a simple difference of means 
test comparing NM to PPP research in four different areas: disease topic, subject 
category, integration score, and specialization score. The mean number of disease 
specific article in WoS is 0.0025 while the mean for PPP is 0.012.  When I do a 
difference of mean test between these two variables I find that there is a statistical 




scores of NM and PPP articles. However, I could not find a statistical difference in the 
subject categories or integration scores between WoS and PPP articles.  







NM and PPP Pr(|T| > |t|) 
Disease 0.0025 0.012 -0.0093 0.0003 
Subject Category 0.008 0.017 -0.009 .03 
Integration 0.784 0.788 -0.004 .51 
Specialization 0.272 0.351 -0.078 0.001 
 
 Third, I analyzed the organizations working with PPPs and doing NM research. 
Again this analysis gives insight into the differences between PPPs and NM scholars. The 
organizations working with PPPs and the main organizations doing NM research are very 
different. First, many of the top organizations doing NM research are from Asia. Of the 
top 20 NM organizations, 12 of them are from Asia. I suspect that this is because Asian 
governments have invested a lot of money in nanotechnology research (Guan & Ma, 
2007; Hullmann & Meyer, 2003). When I further examine the top organizations 
conducting NM research, very few of them collaborate with formal PPPs. For example, 
the Chinese Academy of Sciences has 1,188 nanotechnology articles, but only 
collaborates with formal PPPs on 12 publications. Again this is further evidence that NM 
and PPPs are operating in different spaces.  
The top organizations partnering with formal PPPs are mostly in Europe and the 
USA. There are only two Asian or African organizations that are ranked as top 
organizations that partnered with PPPs. Table 21 summarizes these results. 
TABLE 21 TOP ORGANIZATIONS WORKING WITH PPPS AND DOING NM RESEARCH 
  Partners with PPP # Articles   NM Organization # Articles 




2 Univ Oxford 190  Harvard Univ 436 
3 Univ Utrecht 183  Nat’l Univ Singapore 400 
4 Univ Cape Town 168  Fudan Univ 378 
5 Harvard Univ 156   Seoul Nat’l Univ 371 
6 Leiden Univ 140  MIT 368 
7 Johns Hopkins Univ 133  Sichuan Univ 355 
8 Univ Washington 133  Shanghai Jiao Tong Univ 354 
9 Univ London Imperial Coll 113  Zhejiang Univ 353 
10 Univ Amsterdam 107  Nanyang Technol Univ 296 
11 Univ Groningen 101   Peking Univ 270 
12 George Washington Univ 96  Nanjing Univ 268 
13 Univ Liverpool 87  Univ Michigan 268 
14 Radboud Univ Nijmegen 85  CNRS 259 
15 Seoul Nat’l Univ 84   Nat’l Taiwan Univ 250 
16 Emory Univ 80  Stanford Univ 238 
17 Karolinska Inst 76  Univ N Carolina 237 
18 Vrije Univ Amsterdam 72  Southeast Univ 230 
19 Univ N Carolina 64  Univ Illinois 227 
20 Mahidol Univ 59   Univ Calif San Diego 224 
 
Conclusion 
 In the quantitative analysis, I investigated two aspects of NM and public private 
partnerships. First, I analyzed the effect of medicine sales and disease burden on research 
output and I had three hypotheses. The first hypothesis was that medicine sales would be 
positively correlated with R&D for that disease area 
 H1.1: High medicine sales in the USA for a certain disease are associated with 
 more NM publications and patents for that disease area 
I find that this hypothesis was not supported. Medicine sales do not relate to NM 
publications or patents.  
 The next hypothesis predicted that disease burden would drive more NM research. 
The literature suggests that disease burden has some relationship with research funding 




H1.2a: Diseases with high burden of disease have more NM publications and 
patents 
H1.2b: Diseases that have increasing disease burden have more publications and 
patents 
 These hypotheses are also not supported. There appears to be no relationship 
between disease burden and NM publications and patents. Therefore, even though other 
studies show that there is a relationship between disease burden and publications 
(Vanderelst & Speybroeck, 2013), this relationship does not hold in this analysis.  
 The third hypothesis tests whether DoP receive less attention than diseases that 
affect mostly rich countries.  
H1.3a: There are fewer NM publications and patents on DoP compared to non-
DoP controlling for medicine sales and disease burden 
H1.3b: DoP with more PPP funding (hotdop) have more NM publications and 
patents than other DoP with less PPP funding 
 These hypotheses are verified. From this set of data, I determine that DoP are less likely 
to have NM publications and patents than non-DoP. The only database that did not follow 
this pattern was PPP research. For this population, their research is more likely to be 
about DoP. Given that the missions of most the PPPs in the dataset relate to creating 
medicines and vaccines for DoP, these results make empirical sense.  
 The second part of my quantitative analysis examines the publication patterns of 
public private partnerships. My initial hypotheses that PPPs are more active in NM than 




nanotechnology. In light of this conclusion, I compared the research of PPPs and other 
organizations. Did they have different foci?  
 I find that PPPs and NM articles in WoS are different. NM and PPP articles focus 
on a different set of diseases, publish in journals with distinctive subject categories and 
operate in two different regions of the world. NM articles tend to focus on diseases that 
receive a lot of attention in western countries such as cancer and periodontal disease 
while PPPs specialize in DoP research. Another difference between PPP and NM articles 
is that different organizations and regions of the world were involved in PPP and NM 
research. PPP researchers are centered in Europe and the USA while NM researchers 
span the globe with a major presence in Asia.  








This chapter gives the results of website content analysis and interviews of public 
private partnerships. There were several goals of the qualitative analysis. First, I wanted 
to understand the role of PPPs and how they are better suited than the government or 
companies for doing R&D for DoP. Second, I wanted to verify the quantitative data. The 
quantitative data shows that PPPs are not active in NM research and that they have 
different research foci than NM scholars. Do the interviews and website analyses confirm 
that PPPs are not doing NM research? Finally, do the qualitative data show unknown 
links between the actors and research?  
 To my knowledge, there are 28 formal PPPs that do health R&D and I studied all 
of them in this analysis. Each of the PPPs have detailed websites that clearly state their 
goals and funding sources. Moreover, some of the websites feature reports about their 
progress, financial statements and the advantages of the PPP model for drug 
development. In addition to reviewing the websites, I conducted 14 semi-structured 
phone interviews of scientists and managers within PPPs or with NM. The interviews 
lasted about 30 minutes and after I collected all the website information and interviews, I 
transcribed the interviews and coded the data in Nvivo. Chapter 3 gives more details 
about the methods I used for the qualitative data.  
 This chapter begins by discussing PPPs’ self-ascribed definition and purpose. 
PPPs are aware that they need to be clear about their mission and why they are an 




and the effects their funding has on R&D. Third, I analyze the partnerships’ publication 
strategies, intellectual property policies and their research in NM. Finally, close the 
chapter by discussing the globalization of PPPs. 
History of Health PPPs 
The current form of health R&D public private partnerships (which are often 
called product development partnerships) began around 2000. Before 2000 there were 
only a few health PPPs, but after 2000, dozens of them sprung up (Cohen, 2006). At that 
time, several factors arose that created a public buzz to address DoP. In 2000, there was a 
lot of public outrage directed at pharmaceutical companies because they refused to 
provide low-cost HIV medicines to victims in poor countries. In response to the negative 
publicity, many of the big pharmaceutical companies changed their policies on medicines 
for DoP. The pharmaceutical companies began conducting DoP R&D and they gave 
away their technology to researchers working on projects targeted for poor communities 
(The Economist, 2013). Moreover, in 2000, the United Nations launched the Millennium 
Development Goals (MDGs) and put global health issues for the poor on the world’s 
political agenda. This made people more responsive to the needs of the poor and it put 
public pressure on countries to find solutions for DoP. Similarly, celebrity activists, such 
as Bono and Angelina Jolie, emphasized global health issues and they encouraged the 
popular media to cover their efforts.  
Finally, a significant factor that launched PPPs around 2000 is that several large-
profile organizations, such as the Bill and Melinda Gates Foundation, began to fund 
various projects on DoP. But unlike previous efforts, the foundations wanted to change 




(Cohen, 2006). PPPs were seen as a vehicle to leverage the advantages of the private 
sector to address poverty issues.  
There was not an official launch date of health PPPs and one PPP manager recalls 
that his partnership was formed very informally. He says, 
“We were founded by a group of global health organizations, sort of informally. 
In 2000 in a meeting in Cape Town, there were a lot of global health groups in 
the topic of TB and the resurgence of TB sort of came up. And from that meeting 
the concept of [PPP_A] was conceived. And then it took a couple of months or 
years to sort of get off the ground in terms of operation.” 
Another way that PPPs began was that large non-profit/government organizations 
got together to form PPPs. One organization that started about four PPPs in the early 
2000’s was the WHO-TDR. The WHO-TDR website explains that they made a concerted 
effort to create several PPPs because they believed that DoP research was getting too 
complicated for one organization to manage. The WHO-TDR director, Carlos Morel, 
explained the importance of PPPs by saying, 
“Some people asked: ‘Why are you creating these PPPs? It is going to create 
more competition for TDR.’ Our response was we wanted new products as 
quickly as possible, and in some cases it [PPP] was more efficient.” 
Types of PPPs 
 PPPs can be divided into two broad groups. The first types of partnerships 
conduct biomedical research and develop new medicines.  Two prominent PPPs that 
focus on biomedical research are The Program for Appropriate Technology in Health 




website says their goal is to “drive the development and early implementation of 
innovative diagnostic tests that have a high impact on patient care and disease control in 
low-resource settings” 
The other types of partnerships focus on advocacy, education and medicine 
pricing partnerships. Rather than developing new medicines, these PPPs find solutions to 
get current medicines to individuals in poorer nations.  Though I categorize the PPPs into 
these two distinct groups, some PPPs, especially the large ones, do both biomedical R&D 
and downstream health advocacy.    
The biomedical R&D PPPs, which is the main focus of this dissertation, can be 
further divided into in-house R&D PPPs and R&D project managers. The in-house R&D 
PPPs function like academic research labs by getting research grants from large 
foundations and government agencies for particular project and they often partner with 
universities. In fact, many in-house PPPs were started by academics.  
A good example of an in-house PPP that works closely with a university is the 
Sabin Vaccine Institute. Peter Hoetz, who currently holds an academic post at the Baylor 
College of Medicine, founded Sabin and most of Sabin’s vaccine development in housed 
within Baylor. Moreover, Sabin accesses many of Baylor’s resources such as grant 
services and the IRB process, to decrease costs. A manager at Sabin says, 
“We leverage the fact that we maximize the resources because we are imbedded 
in institutions that already have a lot of resources. For instance I don’t have to 
worry about ethic reviews because we utilize the IRB of our institutions … 




recreate the bureaucratic and administrative system….It’s like having a 
biotechnology company embedded within an academic institution.” 
The other type of R&D PPP is a knowledge facilitator. Rather than doing all the 
research in-house, these PPPs contract the work to other scientists. A typical scenario for 
these partnerships is that they receive a research grant and then they redistribute the 
money to other research labs to do the work. For example, in an interview a person from 
one PPP says 
 “Well for each project we have to write a proposal to a donor and get funding 
for a specific scope of work. PPP_X doesn’t just get money to do whatever they 
please. We write grant applications to do specific activities and often those 
applications are joint applications between PPP_X and some of our partners. And 
then depending on the role of PPP_X it might be managing the project or grant 
out the money to the collaborators.”  
Another manager from a knowledge facilitator PPP explains that  
“PPP_B’s R&D expenditure is generally not direct expenditure, but is in the form 
of grants and contracts with external parties who perform certain tasks at its 
request.” 
 In the interviews I asked PPPs about their choice to outsource R&D projects 
instead of using in-house R&D labs. Most of the knowledge facilitator PPPs responded 
that outsourcing R&D allows them to better manage the projects and it saves them money 
because they do not have to maintain expensive facilities.  
Another difference between PPPs is that some focus on specific diseases while 




study, 8 out of 28 PPPs are disease-specific PPPs. The most common diseases that PPPs’ 
are targeting are HIV/AIDS and tuberculosis (TB). Often the disease-specific PPPs 
address multiple aspects of that DoP. For example, Aeras wants to advance TB R&D and 
it works with researchers, helps with clinical trials and does policy/advocacy work.  
Other PPPs focus on specific methods and techniques. In general, these PPPs 
work on platform technologies that can be used on several disease areas. For example, 
The Foundation for Innovative New Diagnostics (FIND) specializes in developing 
diagnostic tools and they are working on diagnostics for malaria, Human African 
Trypanosomiasis and TB. Method-specific PPPs believe that they are better able to 
produce a product by working on one aspect of the health system. Once they completed 
their task, method-specific PPPs partner with another organization to bring a product to 
market.  
 As mentioned before many PPPs do more than just R&D. Several PPPs 
concentrate on other aspects of the health care system such as changing the price 
structure of necessary medicines, improving logistics in order to get medicine to their 
final destination, and ensuring that health clinics are stocked with the necessary drugs. 
For example the Global Alliance Vaccine Initiative’s (GAVI) mission centers on 
immunizing the world’s poor. GAVI does not conduct research but rather it does a 
variety of things such as shaping the vaccine market and strengthening the health delivery 
systems. GAVI believes that one of the main problems of healthcare in developing 
countries is that medicine prices are too high so they are working on unique market and 
pricing initiatives, such as advance purchase commitments, in order to make DoP 




Importance of PPPs 
PPPs are keenly aware that they need to describe their purpose and how they are 
different than traditional pharmaceutical companies. Most PPPs dedicate several pages of 
their website to describing PPPs, why they exist and the value they bring to R&D. For 
example, Medicines for Malaria Ventures (MMV) devotes sections of their webpage to 
describing PPP and product development partnerships (PDPs). They say that PPPs (which 
are also called PDPs) 
“Act as a facilitator, bringing dedicated sources of funding and know-how to 
committed researchers so they can collaborate on the right projects to fulfill the 
objectives of the PDP’s mission. The specific objectives of individual PDPs vary, 
but the basic mission is the same: to develop pharmaceutical products for use as a 
public good to address the health needs of vulnerable populations in the 
developing world.” 
PPPs view themselves as changing the traditional model of pharmaceutical drug 
manufacturers in order to provide medicines for the poor and underserved populations. 
They employ terms such as “uniquely positioned” or “bridges” to show how crucial they 
are for DoP R&D. PPPs highlight the realization that one organization cannot fully bring 
a drug to market efficiently and that they are uniquely positioned to fill that gap. One 
manager at a PPP explains that, 
“…if you go back 50 years ago you had one chemist and a doctor who would try 
a medicine out on patients. Now you have a whole range of skills from chemists to 
biologists to toxicologists (who make sure things are safe). It’s become much 




Not only do PPPs view themselves as bridging a skill gap between different 
sectors, but also they think they are bringing together actors with different incentives. 
Industry and academia have different reward systems and structures. Industry is 
concerned with generating a profit, while academics are more concerned with generating 
top research. As one manager says, 
“Academic cultures and industrial cultures are by definition different... Which 
means the goal needs to be a concrete goal for the industry which is not the same 
for the academic environment who can have a lot of benefit from excellent 
publications but will never lead to a concrete drug that will be brought to the 
market.” 
However, PPPs can bridge the two cultures and make it easier to work together. A 
partnership is not motivated by profit or publication counts. Rather they care about 
producing the best medicine for the lowest cost and as a result, PPPs feel they fill a void 
left by pharmaceutical companies and academics. 
  A second factor that PPPs use to justify their competitive advantage is that they 
believe they are the best organizations at picking technologies that have the greatest 
potential to create medicines. PPPs maintain that academia and industry have incentives 
that prevent them from choosing a viable research path. PPPs on the other hand, can be 
impartial and better judges of research lines. One PPP manager compares PPPs to venture 
capital firms. He says that  
“The venture capital industry is all about putting the right projects together, 
picking the right things together, and funding them for as long as they need and 




It’s a very different funding model than say an academic crowd where you write a 
proposal and get money for 5 years. And at the end of 5 years you have to explain 
what you’ve did with it. So I think when you look at the big consortia [PPP] 
model it’s better suited to the venture capital model. Let pay be based on rewards 
and stop if it’s not working.” 
The PPPs manage and “prune” research portfolios in order to maximize the potential of 
the research. If a certain research path is a dead-end, PPPs feel that they can quickly end 
them.  
 Finally, PPPs repeatedly say that they change the lack of commercial interest for 
DoP. Most of the literature on DoP discusses the market failure associated with R&D for 
these diseases (Kremer, 2002). They reason that pharmaceutical companies do not have 
an incentive to develop medicines for these diseases because companies could not make a 
profit from all of their work (Kremer, 2002). One PPP website says that 
“PDPs address the lack of commercial incentive to undertake R&D for vaccines, 
diagnostics, and drugs for neglected diseases of the developing world. They use 
public and philanthropic funds to engage the pharmaceutical industry and 
academic research institutions in undertaking R&D for diseases of the developing 
world that they would normally be unable or unwilling to pursue 
independently…” 
This PPP discusses how they use funds from several different sources in order to get 
different participants to pursue the same project. A manager at a PPP explains that 
partnerships lower the risk to companies. If an individual company tries to develop a 




by partnering with a PPP, the company is less exposed to non-productive research 
portfolios because their R&D expenses are pooled with other investors. The manager 
explains that  
“In order for a company to make an investment in developing a technology and 
providing it…the technology has to make sense financially for them and PPP_B 
fills in the gap is by helping to de-risk the process.” 
Nanotechnology and PPPs 
A key goal of this dissertation is to understand the role that PPPs play in NM 
research. At the outset of this dissertation, there was some hope that PPPs would be 
heavily involved in NM research for DoP. Much of the nanotechnology literature stated 
that nanotechnology could be used to address disease of poverty and much of the research 
on DoP was done by PPPs. As a result, I expected partnerships to do significant amounts 
of DoP NM research. However, there was very little bibliometric evidence of PPPs 
authoring or funding NM research. During the interviews, I asked the PPP managers and 
scientists whether they used nanotechnology for DoP R&D and the managers and 
scientists gave a wide range of answers about whether they use nanotechnology for DoP 
research. Several PPPs are actively engaged with nanotechnology and believe that it is a 
smart research path, while other partnerships think NM is not good for DoP. The sample 
can be loosely divided into pro-nanotechnology and anti-nanotechnology organizations. 
The pro-nanotechnology organizations are conducting NM research and many of 
them are working on novel drug delivery systems such as encapsulating medicine inside 
nanoparticles or creating nanoneedle patches that deliver medicines. Some of the pro-NM 




“Nanoparticles are not only [good] for delivery drug, but you can imagine many 
things. There is no limit to how you imagine nanoparticles… [there] are so many 
applications of nanotechnology because you can make smart nanoparticles.…You 
can track down your drug, do diagnostics… you can do many things.” 
Most of the other pro-NM interviewees are less optimistic about NM, but they think it 
should be investigated. They believe that nanotechnology could be helpful for DoP 
because the current medicines for DoP are not effective. New NMs could shorten 
treatment times, have fewer side effects and simplify the treatment regimen. 
“The challenge is they [nanomedicines] are all novel…But hey if someone 
doesn’t start, then the data is never compiled. So even though we don’t know if 
any of these things in our hands will become licensed, but we’re evaluating them 
because we need to ensure that we have different alternatives.”  
 Another pro-NM interviewee thought nanotechnology had potential, but the initial 
optimism of the technology has waned. Her organization partners with nanotechnology 
scientists for drug delivery systems, but nanotechnology is a small part of her R&D 
portfolio. The manager says that, 
“I think with every new technology there’s always a spike of initial excitement 
and enthusiasm where people get excited about it and think this is the next big 
thing and everything is going to be nano in the future or everything will be needle 
free in the future. And then with more work and knowledge it becomes more 
tempered. People realize nano may be good for certain things but it’s not going to 




This pro-NM manager believed that nanotechnology could be useful for developing 
medicines for DoP, but NM will be one piece of a multi-faceted approach. Interestingly, 
the scientists and managers most excited about nanotechnology were more closely related 
to academia while those managers that worked on DoP advocacy and price controls were 
less likely to think NM is useful for DoP.  
 The anti-NM PPPs do not pursue nanotechnology and they do not think it is 
useful for DoP. Most of the scientists thought NM would be useful for other medical 
areas, but not for DoP. The main criticism of the anti-NM scientists focused on the cost 
and regulatory constraints of the technology. They worried that NMs would be too 
expensive to manufacture for drugs that require a very low price point. A manager at an 
HIV PPP says that 
“We have to be pennies on the dollar for what our products are and governments 
to buy them and have them a part of their public health programs. Any technology 
that requires sophisticated manufacturing or high cost manufacturing is… though 
probably viable from a medical perspective, not viable from a cost perspective. So 
we had to shy away from a lot of the more unique devices simply from cost.”  
This manager recognizes that NM could be a potential solution for DoP but her 
organization is not pursuing NM for HIV because she believes that the high costs of 
fabricating nanoparticles would be too expensive for low cost HIV/AIDS medicine.  
 Another criticism of NM is that it will take too long for it to get through clinical 
trial and therefore, anti-nanotechnology PPPs believe they should use traditional 




 “The regulatory pathway to get these things through the approval processes are 
 a little complicated than if you want to use a protein bounded to a di-hydrogen.” 
Funding 
 The formal PPPs in this study received their funding from a variety of sources but 
the most prominent funders of PPPs are large foundations, particularly the Bill and 
Melinda Gates Foundation. Almost all the PPPs in this study have funding from the Bill 
and Melinda Gates Foundation and in most instances the Foundation provided the initial 
seed funding. Similarly, other studies found that the Bill and Melinda Gates foundation 
heavily dominated PPP funding. Moran et al. estimate that the Bill and Melinda Gates 
Foundation provided about 50% of formal PPP funding in 2007 (Moran et al., 2010) and 
in general, only a few organizations provide the bulk of PPP funding. The data mention 
the same donors such as the Bill and Melinda Gates, NIH, and USAID. PPPs reliance on 
a limited number of organizations makes them beholden to a few organizations and their 
agendas. If the Bill and Melinda Gates Foundation moves away from DoP R&D, formal 
PPPs could not survive. 
 The PPPs approach corporate funding very differently. Some PPPs receive lots of 
funding from big pharmaceutical companies (big pharma) such as Merck or Johnson & 
Johnson while others tend to stay away from big pharma. One PPP says that big pharma 
is not interested in their organization because  
“There is not a lot of commercial interest of the vaccines that we have in our 
portfolio versus something like malaria that may have multiuse.” 




Another challenge for PPPs is that there was a lack of overall funding for R&D. 
During the recession in the late 2000s there was less money and all the donors, including 
large government agencies, had to slow down their outlays. One scientists says that  
“It seems to me that it’s getting harder to do the work because of the funding 
environment. It’s probably getting harder for everyone to work.” 
The same scientist goes on to say that finding research money for DoP R&D is  
“…a struggle because you look around and there are cancer grants from the 
university and things such as that and it’s harder to find opportunities other than 
the NIH to keep your research going.”  
As a consequence, several PPPs mentioned that they are targeting new sources of 
funding. One PPP in this study received funding from Fundación Carlos Slim, a 
foundation that has not traditionally supported biomedicine research. In addition, this 
same PPP targeted high net worth individuals for support on specific projects. In one 
case, the PPP was able to convince a wealthy donor to recruit other high net worth 
individuals to donate to the PPP.  
Another funding diversification strategy is to find organizations that will match 
research money from large foundations. By soliciting matching donations, PPPs can get 
more research money and the donors have more confidence that their investment is going 
to a reputable cause because someone already vetted the project. In addition, giving 
matching donations prevents the donor from spending resources sorting and choosing the 
best project since soliciting scientific proposals can be very technical and expensive. 
Often smaller governments, such as Denmark, will give matching funds. One PPP 




“We can’t rely on a single funding mechanism and you certainly can’t rely on just 
federal NIH type of mechanism. So we have a very diverse portfolio. Certainly we 
have the Bill and Melinda Gates Foundation …However, in the latest 4-5 years 
we’ve gathered funders that co-fund the Gates Foundation.” 
A source of non-monetary support is to use another organization’s lab and 
equipment. In this strategy, money may not exchange hands, but PPPs can save money by 
sharing resources. A PPP manager explains that  
“the NIH will give us money, where we don’t directly get the money, but we’ll say 
we need to have this tested and they’ll do it without charging us and without 
giving us money.” 
Also PPPs can get compounds and formulas from companies without being charged 
licensing fees. Again this is a non-traditional form of funding.  
“So what we can do is go to a pharmaceutical company and ask them for 
compounds they are developing for HIV treatment and get licenses to them. We 
have done that for 6-8 compounds. So we go to big pharma like J&J and Pfizer 
and Merck. They have all given us compounds and we can develop them using 
donor funds and collaboration with universities.” 
 Finally, a major challenge expressed by PPPs is that donor organizations put strict 
restrictions on their research money, which hinders the PPP’s ability to transfer money to 
different projects. For example, the donor may require that funds only be spent on a 
particular HIV project and the funding cannot transfer to another experiment. In addition 




“So reporting back to donors is extremely time consuming. Each donor is very 
specific about what their money can be spent on and we have to report back. 
That’s an incredibly involved effort.” 
In addition to funding restrictions, some donors specify the partners of PPPs. For 
example Fundación Carlos Slim Foundation requires that recipient organizations partner 
with Mexican institutes. To comply with all the requirements of donors, PPPs must hire 
full time staff members to handle the grant logistics.  
Patents and Publications 
The quantitative analysis uses publication and patents as the main dependent 
variables and therefore I needed to verify that PPPs publish and patent their research. I 
found that PPPs are very active in publishing. On their websites PPPs often cite their high 
publication rates as measures of success. For example, a Sabin Vaccine Institute report 
they highlight that one of their main accomplishments in 2012 was that they had over 25 
peer-reviewed journal articles for that year. 
 PPPs publish for a variety of reasons. First, unlike companies that want some 
information to remain a secret in order to have a competitive advantage, PPPs broadly 
share information with other organizations. A manager at a large PPP says that, 
“Publishing and disseminating information is a key part of what we do. We have 
principals of global access that we work with. Global access means that the 
technology we work on should be accessible as well as the information that we 
generate should be accessible. So we typically strive to publish our work as much 
as possible and build that into our agreements with our partners that the 




This manager expresses that sharing information is a key part of her organization’s 
strategy and that publishing is a major part of that effort.  
 Another factor that pushes PPPs to publish is that many PPPs have academic 
cultures. As discussed before, some PPPs were founded by academics and many of them 
are closely associated with universities. The academic focus on publishing carries over to 
PPPs.  
Patenting is more complicated for PPPs than publishing. Each PPP approaches 
patenting slightly differently; however, one major theme across the organizations is that 
they use patents to protect themselves. Several PPPs expressed concern that other 
organizations could prevent them from working on certain projects or steal their IP if they 
do not proactively patent their technology. One manager gives a hypothetical situation in 
which a research partner sees that a technology has market potential and in order to make 
money, the partner patents the technology. Once the technology is patented, the partner 
could block the PPP from developing a low cost medicine and instead the partner would 
create an expensive drug.  
“We approach the patenting aspect mostly to protect not because we foresee 
having some royalties generated. We protect mostly so that we can make sure no 
one interferes with us advancing this program.” 
 Another way PPPs deal with intellectual property is by working closely with 
industry to have more access to the necessary intellectual property for their work. PPPs 
and pharmaceutical companies will develop special agreements that allow non-profit 
organizations to develop medicines for DoP without paying licensing fees. The 




the PPP can use the technology for humanitarian purposes. The PPP FIND has a long 
discussion about their use of patents on their website. FIND says that 
“Industry partners assign all rights to FIND for royalty-free use of their 
technology in the public and private non-profit sectors in high endemic countries, 
while the industry partner retains distribution rights for developed countries and 
the private sector in developing countries. This enables the partner to recover 
R&D costs and to create the returns needed to develop new technologies.” 
FIND goes on to explain that having different patent protection for different markets has 
allowed it to work with more companies.  
“Our IP model has been successfully validated with industry partners and has 
contributed to an important and increasing number of contracts signed with large 
and small-sized companies.” 
Globalization of PPPs 
 In the quantitative analysis, a major finding is that PPPs and their partners tend to 
be based in Europe and the USA while organizations doing NM research have a large 
presence in Asia. During the interviews, I asked respondents about their R&D partners. 
From the interviews and websites I gathered two underlying trends among formal PPPs. 
First, 26 out of the 28 formal PPPs are headquartered in the USA or Europe. This 
evidence supports the bibliometric data that shows that formal health PPPs are mainly 
creations of the West. Even rich Asian countries, such as Japan, have not been active in 
DoP R&D and only within the past year has Japan started a started a PPP called the 
Global Health Innovative Technology Fund (GHIT). Japan’s late entry into PPPs is noted 




“From a global perspective, countries in Europe and North America often see the 
issue of global health as a component of their diplomatic or growth strategy. 
Although Japan is one of the largest donors of overseas development assistance 
and also one of the leaders in health technologies innovations, its efforts toward 
global health have lagged somewhat.” 
 Even though many formal PPPs are headquartered in Europe and the USA, it is 
not true that these organizations have no presence in Asia and Africa. Most of the PPPs 
have African and Asians partners and many of the PPPs have brick and mortar office on 
these continents. Unfortunately, the partnerships are unequal. Most of the developing 
countries do not have R&D facilities, but rather those countries only host clinical trials. 
Hosting clinical trials are important, but the host nation does not build significant R&D 
capacity. However, this trend is changing. The Brazilian, Mexican, Indian and South 
African governments funded PPPs and are doing more fundamental R&D for DoP.  
Conclusion 
The interviews and website analysis confirmed that health PPPs are important for 
DoP research, but they are not major players in NM research. Some PPPs explore 
nanotechnology for DoP medicines, but many believe that these medicines are too 
expensive and it will take too long for regulators to approve these drugs. As a result, 
some PPPs stay away from nanotechnology in favor of more traditional technologies. 
Moreover, the analysis shows that PPPs are global entities, but their headquarters, donors, 
and main laboratories are located in the USA and Europe. This confirms the bibliometric 
data that PPPs are located mostly in Western nations while NM research has become a 




The next chapter reviews the major findings and discussion policy implications of 




CHAPTER 6: CONCLUSION 
Introduction 
 The previous two chapters discuss the findings from the quantitative and 
qualitative data analyses. This chapter summarizes the findings and gives implications 
and policy recommendations. The recommendations focus on increasing R&D and 
improving the effectiveness of PPPs for DoP research. I suggest a variety of policies such 
as simplifying the regulation process for new medicines and diversifying research 
funding.  
Summary of Conclusions/Implications 
 My first research question investigates inequality in NM on three dimensions: 
USA Medicine sales, disease burden, and DoP. The analysis showed several interesting 
relationships between NM R&D and disease burden, medicine sales, and DoP. First, the 
WoS and PubMed data are highly correlated (0.96), while WoS and PatStat data are not 
as highly correlated (0.64). This is evidence that the patent and publication databases 
measure two different phenomena. Publications are more likely to relate to basic 
research, while patents are more likely to relate to development.  
 Despite the observations from the correlation matrix, I am limited in my 
interpretations because only one of the variables in the analysis, dop, has any significant 
relationship with NM R&D. I found that DoP have significantly less R&D than non-DoP.  
In WoS, DoP have 0.24 times the number of publications as non-DoP. From this analysis, 
I could not determine if the other variables in the model, USA medicine sales and disease 
burden, have any relationship with NM R&D. These findings are important because 




component of their criteria to fund research and I showed that the relationship between  
disease burden and NM research is unclear.   
 Next, I examined a subset of publications that contain only DoP articles to 
determine if DoP research increases as PPP funding increases. I found that there is a 
small relationship between PPP funding and DoP research. If PPP funding for a disease 
of poverty increases by $1 million dollars, then the expected number of NM publications 
increases by 1.003 times. Therefore, donors must $1 billion to see an increase of one 
journal publication. Given the weak financial climate and the difficulty that PPPs have 
finding donors, it is likely that DoP R&D will increase because there is not enough 
money to support the research.  
I also compared PPP research to NM research and I found that PPP and NM 
scientists focused on different diseases, published on different topics, and worked in 
different regions of the world. First, when I compared the types of diseases that PPP and 
NM scholars study, I found that PPP publications mainly focus on DoP while the 
majority of NM articles are about cancers, periodontal disease, and Alzheimer’s disease. 
In addition, PPPs published in journals that focused on immunology and infectious 
diseases while NM scholars published in journals with subject categories such as 
biophysics, biomaterials, and oncology. These results align with my regression analyses, 
and they show that PPPs and NM scientists study different areas of science. Scientists 
originally hoped that nanotechnology would be used to make medicines for DoP, but 
PPPs, who are the main actors in DoP medicine development, have different research 
agendas than NM researchers. Unless PPPs and NM scientists align their interests, it is 




 An unexpected difference between NM and PPP publications is that they operate 
in very different regions of the world. Asian and American institutions are very dominate 
in nanotechnology R&D while European and American institutes mostly work with PPPs. 
This is further evidence that there is a mismatch between PPP and NM scholars. 
Nanotechnology research is much more globalized while PPP research is still 
concentrated in Europe and North America. Other studies also find that Asian countries 
and other emerging markets have prioritized nanotechnology research (Liu et al., 2009; 
Maclurcan, 2005). In many emerging economies, there is a government push to do 
nanotechnology R&D and as a result emerging economies are becoming hubs of 
nanotechnology R&D. However, innovation for DoP has not received as much attention 
in emerging economies. None of the PPPs are headquartered in emerging markets and 
only two are based outside of Europe or American. Moreover, even rich Asian countries, 
such as Japan, are not heavily involved with global health initiatives and PPPs. An 
implication of this finding is that R&D for DoP is only done in the West even though 
science and technology research is globalizing and moving eastward. If other parts of the 
world do not invest in DoP research, then it is likely that this type of research will remain 
under funded and lag behind other research areas.     
Despite the differences between PPP and NM research, they both have higher 
integration and lower specialization scores than science a whole. This means that PPP 
and NM scientists integrate knowledge from a diverse range of subject categories and 
they publish their work in a variety of journals. The literature suggests that high 
integration scores and low specialization scores lead to more innovative science because 




al., 2005). From the evidence, NM and PPP publications both appear to be more 
innovative than science as a whole.  
 My next set of questions examined PPPs in order to understand their mission, the 
benefits of that organizational structure and their relationship with nanotechnology. I 
collected data from PPP’s websites and conducted interviews with PPP managers and 
scientists. First, I found that most PPPs started around 2000 due to a tremendous global 
pressure to address DoP. A variety of actors, such as the United Nations, pharmaceutical 
companies, and celebrities rallied around improving global health and they invested 
billions of dollars starting PPPs.  The window of opportunity that opened in 2000 for DoP 
research was crucial for PPPs to receive funding and develop DoP medicines. An 
implication of this finding is that future PPPs may need a similar window of opportunity 
to raise funds. Without a global emphasis on issues, it may be difficult launch a global 
PPP to target other areas related to poverty.  
 Another finding is that there are both pro and anti-nanotechnology PPPs. The pro-
nanotechnology PPPs believe that nanotechnology could offer solutions for DoP and 
scientists should explore this new area for DoP medicines, while the anti-nanotechnology 
PPPs, believe that nanotechnology is too expensive for low cost DoP drugs and that the 
regulatory process for NMs will be too cumbersome. Instead of doing NM DoP R&D, 
anti-nanotechnology firms believe that PPPs should use standard techniques to create 
cheaper DoP medicines with shorter regulatory timelines. The anti-nanotechnology 
position has implications for emerging technologies. If governments do not develop 




technology will only be used to solve rich world problems and as a result the technology 
will increase inequality.   
The evidence suggests that DoP NM research will not become a major stream of 
research and that NM has not progressed as fast as scientists initially hoped. Even though 
the pro-nanotechnology PPPs conduct NM R&D, it is a small part of their overall R&D 
portfolio. Until NM becomes a standard medical technology, it will not be heavily used 
by PPPs for disease of poverty R&D. As a result, nanotechnology could increase health 
inequality rather than decrease it. The technology will first be used on diseases that affect 
the rich, such as cancer and Alzheimer’s and after it is adopted in high-income markets, 
then DoP scientists will use the technology.  
 Another conclusion from the qualitative analysis is that PPPs are only funded by a 
few organizations. Most of the PPP funding comes from the Bill and Melinda Gates 
Foundation and large government organizations such as the National Institutes of Health 
or British aid agencies. At one point the Bill and Melinda Gates Foundation supplied over 
half the formal PPPs fundeing (Moran et al., 2010). An implication of this finding is that 
a small donor base makes PPPs more vulnerable. If the Bill and Melinda Gates 
Foundation stops supporting DoP research then these partnerships could shut down. PPPs 
recognize their predicament and they are seeking new sources of funding. Unfortunately, 
fundraising draws resources and personnel away from R&D, which slows down drug 
development.  
 Overall, PPPs work well with each other, and they often collaborate on projects. 
In the interviews, the PPP managers mentioned that they want to partner with 




PPPs want other non-profit drug developers to succeed, so that they can use the results to 
find medicines and vaccines for their particular disease. Moreover, PPPs informally 
coordinate with each so that they do not replicate the same research. These collaborations 
have led to a global network of health PPPs and it is a major strength of the model. The 
networks facilitate knowledge transfer between the organizations, which causes them to 
develop DoP medicines quicker.  
 Finally, PPPs are active in publishing and patenting their research, and many of 
them cite their publication counts as one of their top accomplishments. However, an 
unintended consequence of focusing on publishing is that PPPs could turn into research 
institutions that are more concerned with academic achievement and not producing 
medicines.  
PPPs approach patenting very differently than publishing. They are more strategic 
with patents and use them as shields so that other organizations cannot block them from 
doing R&D. PPPs are very clear that they do not patent to make money, but rather they 
patent an invention and allow others to use the technology for free. A downside to PPPs’ 
patent policy is that they spend a lot of time and resources developing defensive patents. 
If the patents rules were changed to help PPPs, then they would have more time and 
money for research. Given the current set of laws, patenting will remain a major a 
priority for PPPs in order to protect themselves.  
Policy Recommendations 
 Below are several policy recommendations from this study.  




 Overall PPPs are at the forefront of DoP research and it is expected that they will 
develop more DoP medicines. Moreover, other studies conclude that PPPs are more 
successful than traditional public research institutions and technology transfer strategies 
for DoP medicine development (Moran et al., 2010; Moran, 2005). If governments want 
to promote DoP research, then they should fund more PPPs.  
Cheaper nanotechnology materials 
 In this study, I examined NM as an example of an emerging technology and I 
found there are pro and anti-nanotechnology PPPs. In order for PPPs to use emerging 
technologies, policy makers must adopt special incentive programs to encourage DoP 
research with emerging technologies. Several PPPs mentioned that they avoid using 
nanotechnology because it is costly. They believe that medicines for DoP have to be 
cheap and that using nanotechnology as a part of the drug delivery system would make 
the medicine prohibitively expensive. Therefore, in order to push PPPs to do NM 
research, governments and private organizations should ensure that nanomaterials are 
cheap. For example, if the USA wants to promote nanotechnology DoP research, then it 
could subsidize the cost of nanomaterials in DoP medicines, which would bring down 
their costs and encourage scientists to uses these materials for drug development. Another 
way to foster R&D is that private companies who are interested in social outreach could 
establish more partnerships with PPPs and provide them with cheap R&D materials. This 
allows the company to get involved with a social project and later the company could use 
the knowledge generated by the PPP to develop other technologies. 




 One reason that PPPs are hesitant to develop DoP NMs is that they fear the new 
medicines will have long approval processes compared to medicines using standard 
techniques. Therefore, to make emerging technologies more appealing for DoP R&D, 
government agencies, such as the U.S. Food and Drug Administration, could offer fast 
track approval processes for them. This will ensure that lifesaving drugs can reach the 
market as fast as possible. However, regulatory agencies must ensure that the fast 
approval processes do not allow sub-standard medicines to be used in poor countries.  
Strengthen foreign partnerships 
 PPPs are largely headquartered in Europe and the USA and middle and low-
income countries have small roles in DoP research. Organizations in low-income 
countries mostly assist with medicine trials, medicine distribution, and manufacturing. 
Other studies also observed unequal partnership in PPPs, which led to asymmetric power 
relationships, poor R&D and diminished economic development (McQuaid, 2000; 
Miraftab, 2004).  
By being on the periphery, organizations in low-income countries do not develop 
high-skill R&D knowledge because they are not involved in fundamental research 
(Miraftab, 2004). In order to decrease these asymmetries, PPPs should develop more 
R&D facilities in developing countries to increase capacity building. Some donors, such 
as Fundación Carlos Slim, require that scientists partner with low-income countries. If the 
donor community adopts more policies that build global R&D capacity, then there will be 
an increase in R&D on emerging technologies from developing countries.  




 Most of the PPP funding comes from a few large donors, such as the Bill and 
Melinda Gates Foundation and USAID. If the donors change their objectives, then PPPs 
could lose the majority of their support and the scientific progress on DoP would be 
severely curtailed. To make PPPs more resilient, they should find donors from a wider 
range of foundations, governments, companies, and private individuals. Many of the 
PPPs in this study are broadening their funding base but the economic depression 
hampered their fundraising capability. Funding is a major issue that prevents PPPs from 
doing more research on emerging technologies such as NM. 
Simplify reporting standards 
 PPPs spend a lot of time tracking and reporting their donations. One PPP manager 
suggests that donors should develop one reporting standard that is used by all the donors, 
so that PPPs could have more time and money to be spent on R&D. However, 
conforming to one standard weakens each donor’s control over their donation and how it 
is spent and reported.  
Change patent protections to help PPPs 
 PPPs are concerned that companies can patent their innovations and prevent them 
from developing technologies and as a result they spend a lot of money and time 
developing defensive patents. PPPs mentioned that the current patent system limits their 
ability to develop medicines for DoP. However, reforming intellectual property rights for 
DoP is very complicated. There are numerous papers on this issue and often scholars give 
competing advice based on their intellectual traditions (Feachem & Sachs, 2002; Global 
Forum for Health Research, 2007; Kremer, 2002).  Webber and Kremer write that “Patent 




be regarded with caution. Undermining patent protection could discourage innovative 
activity on the part of industry, while strengthening patent protection could come at the 
expense of reduced access” (Webber & Kremer, 2001). Despite the complexity, one 
common suggestion is to change the patent laws for low-income countries and medicines 
that target DoP (Kremer, 2002). This strategy would allow PPPs to access the necessary 
intellectual property to develop novel medicines without going through as many hurdles. 
In lieu of such reforms, PPPs make special deals with pharmaceutical companies in order 
to have access to compounds for medicine and vaccine development. Though this 
strategy has worked in the past, it is highly dependent on the largess of big 
pharmaceutical companies. Changing the patent system would allow PPPs to be more 
effective. 
Develop PPPs for other poverty alleviating technologies 
 PPPs are successfully developing medicines for the poor and without their efforts 
many DoP medicines would not exist. Given the accomplishments of PPPs for DoP 
R&D, it may be possible to use the PPP model to address other development problems. 
For example, PPPs could create new seeds and pesticides for subsistence farmers or they 
could build innovative water filtration systems that are specifically designed for low-
income countries.  However, the main hurdle that prevents the PPP model from being 
used in other fields is that scientists and community workers need to find money to invest 
in more innovations for the poor.  
Conclusion 
 Improving global health is one of the major global public goods and many believe 




technologies will not automatically decrease poverty and income inequality. Rather, it is 
necessary to implement a variety of reforms such as strengthening research collaborations 
with developing countries and changing the patent system in order to help emerging 







Below is the thesaurus used to find diseases in the bibliometric databases. 
*=Sub-category of disease 
Abortion 





Benign prostatic hypertrophy 
Bipolar affective disorder 















Chronic obstructive pulmonary disease 
Cirrhosis of the liver 
Colon/rectum cancer 
Congenital abnormalities 







Diseases of the genitourinary system 













Hypertensive heart disease 
Inflammatory heart disease 
Insomnia 



























Melanoma/ skin cancers 
Meningitis 
Migraine 
Mouth/ oropharynx cancers 
Multiple sclerosis 
Musculoskeletal diseases 




















Peptic ulcer disease 
Perinatal conditions (e) 
Pertussis 
Poliomyelitis 
Post-traumatic stress disorder 



































Unipolar depressive disorders 
Upper respiratory infections 












My name is Thomas Woodson and I am a PhD Student in Public Policy at the Georgia Institute of 
Technology (Georgia Tech) in Atlanta GA. For my dissertation I’m studying medicines and public private 
partnerships who do research for neglected diseases.   
 
As a part of my study, I would like to interview you about PPP_X. Would you or someone from PPP_X be 
available for a quick 30min phone/Skype interview about the organization? PPP_X is doing some fantastic 
work on ________ and I've love your insight about the future of drug development for diseases of poverty.  
Please let me know of any questions or concerns that you may have.  Thank you for your consideration, and 
I look forward to hearing from you soon. 
 
Below is the Institutionally Review Board (IRB) approval  
  
Nanomedicine and Public-Private Partnership Research for  
Diseases of Poverty  
Thank you very much for agreeing to speak with me today. As I explained in my e-mail, I am 
doing research on medical applications of nanotechnology (nanomedicine) for diseases of poverty. I am 
also studying how public-private partnerships and other organizations are getting involved in the research 
on diseases of poverty.   
 I am inviting your participation, which will involve a conversation of 30 minutes to 1 hour about 
nanomedicine, diseases of poverty and public private partnerships. In this conversation I will ask you to 
generalize your current work, the applications you see for it, and the motivations behind it. You have the 
right not to answer any question, and to stop the interview at any time. 
 Your participation in this study is voluntary.  If you choose not to participate or to withdraw from 
the study at any time, there will be no penalty. 
 I would like to audio-record this interview. The interview will not be recorded without your 
permission. Please let me know if you do not want the interview to be taped; you can also change your 
mind after the interview starts.  
 I will take notes on our talk in order to use the information in my publications. But I will not use 
your name in my publications, and I will store the recordings and the notes in a secure place with a code 
number so that you could not be identified even if someone got access to them. 
 There may not be any direct benefit to you from this research although my final report may 
provide insights into research on diseases of poverty. I do not know of any risks to you from participating 
in this study, and you can withdraw at any time.  
If you have any questions about the study, you may contact me, Thomas Woodson, (1-404-894-
1039). If you have any questions about your rights as a research participant, you may contact Ms. Melanie 
Clark, Georgia Institute of Technology Office of Research Compliance, at 1-404-894-6942. Thank you for 






School of Public Policy 
Georgia Institute of Technology 
 
 
Your rights as a research participant 
 Your participation in this study is voluntary. You do not have to be in this study if you do not want 
to be. 
 You have the right to change your mind and leave the study at any time without giving any reason 
and without penalty. 
 If you decide not to finish the study, you have the right to withdraw any data collected about you.  
We will destroy any notes or recordings done before that time.  
 Any new information that may make you change your mind about being in this study will be given 
to you. 
 You will be given a copy of this consent form to keep. 
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